WO2002013763A2 - Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline - Google Patents

Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline Download PDF

Info

Publication number
WO2002013763A2
WO2002013763A2 PCT/US2001/025178 US0125178W WO0213763A2 WO 2002013763 A2 WO2002013763 A2 WO 2002013763A2 US 0125178 W US0125178 W US 0125178W WO 0213763 A2 WO0213763 A2 WO 0213763A2
Authority
WO
WIPO (PCT)
Prior art keywords
emmprin
cyp
leu
protein
emmprtn
Prior art date
Application number
PCT/US2001/025178
Other languages
English (en)
Other versions
WO2002013763A3 (fr
Inventor
Barbara A. Sherry
Michael I. Bukrinsky
Original Assignee
The Picower Institute For Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Picower Institute For Medical Research filed Critical The Picower Institute For Medical Research
Priority to CA002418303A priority Critical patent/CA2418303A1/fr
Priority to IL15435801A priority patent/IL154358A0/xx
Priority to EP01962087A priority patent/EP1309346A4/fr
Priority to AU2001283295A priority patent/AU2001283295A1/en
Priority to JP2002518911A priority patent/JP2004505997A/ja
Publication of WO2002013763A2 publication Critical patent/WO2002013763A2/fr
Publication of WO2002013763A3 publication Critical patent/WO2002013763A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention provides a method for the treatment of HIV infection, acquired immune deficiency syndrome (AIDS), rheumatoid arthritis (RA), connective tissue disorders and cancer utilizing antagonists of the ligand/receptor relationship between cyclophilin (CyP) and the human extracellular matrix metalloproteinase inducer protein (EMMPRIN).
  • AIDS acquired immune deficiency syndrome
  • RA rheumatoid arthritis
  • CDP cyclophilin
  • EMMPRIN extracellular matrix metalloproteinase inducer protein
  • the present invention further provides anti-EMMPRIN antibodies and soluble forms of EMMPRIN or
  • EMMPRIN peptides that provide therapeutic activity by modifying the CyP/EMMPRIN binding interaction.
  • the present invention further provides screening assays for the identification of compounds that modify the CyP/EMMPRIN binding interaction.
  • cyclophilin A is, inter alia, involved in the etiology of (1) the symptoms associated with acquired immune deficiency syndrome (AIDS) from HIV infection, and (2) inflammatory disease (e.g., rheumatoid arthritis).
  • AIDS acquired immune deficiency syndrome
  • inflammatory disease e.g., rheumatoid arthritis
  • HIV human immunodeficiency virus
  • AIDS acquired immune deficiency syndrome
  • HIV replication occurs prominently in CD4 + T lymphocyte and macrophage populations, and HIV infection leads to depletion of T cells and eventually to immune incompetence, opportunistic infections, neurological dysfunctions, neoplastic growth, and ultimately death.
  • the core of the HIV viral particle comprises capsid antigen (CA) proteins, together with the viral RNA genome and those enzymes required for early replicative events.
  • CA capsid antigen
  • MA Myristylated matrix antigen
  • the HIV envelope surface glycoproteins are synthesized as a single 160 Kd precursor protein that is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gpl20.
  • Viral gp41 is a transmembrane glycoprotein and gp 120 is an extracellular glycoprotein that remains non-covalently associated with g ⁇ 41, possibly in a trimeric or multimeric form (Hammarskjold & Redosh, Biochem. Bwphys Ada 989:269-280, 1989).
  • HIV is targeted to CD4 + host cells because CD4 acts as the cellular receptor for the HIV- 1 virus (Dalgleish et al., Nature 312; 763-767, 1984; Klatzmann et al., Nature 312:161 -168, 1984; Maddon et al., Cell 47:333-348, 1986).
  • Viral entry into cells is dependent upon gpl20 binding the cellular CD4 receptor molecules (McDougal et al., Science 231:382-385, 1986; Maddon et al., Cell 47:333-348, 1986), explaining HIV's tropism for CD4 + cells, hile gp41 anchors the envelope glycoprotein complex in the viral membrane. While these virus:cell interactions are necessary for infection, there is evidence that additional virus ell interactions are also required.
  • HTV infection is pandemic and HIV-associated diseases represent a major world health problem.
  • Attempts to develop such drugs and vaccines have targeted molecules corresponding to various stages of the HIV life cycle (e.g., reverse transcriptase, late- stage viral proteases, and in the case of vaccines gpl60, g l20 and gp41).
  • Attempts are also being made to develop drugs that can inhibit viral entry into the cell, the earliest stage of HIV infection.
  • the focus of therapeutic intervention has been on CD4 and CCR5, recognized cell-surface receptors for HIV.
  • Recombinant soluble CD4 has been shown to inhibit infection of CD4 + T cells by some HIV-1 strains (Smith et al., Science 238:1704-1707, 1987). Certain primary HIV-1 isolates, however, are relatively less sensitive to inhibition by recombinant CD4 (Daar et al., Proc. Natl. Acad. Sci. USA 87:6574-6579, 1990). Moreover, recombinant soluble CD4 clinical trials have produced inconclusive results (Schooley et al., Ann. Int. Med. 112:247-253, 1990; Kahn et al., Ann. Int. Med. 112:254-261, 1990; Yarchoan et al., Proc. Vth Int. Conf on AIDS, p. 564, MCP 137, 1989).
  • CyP A is a 19 KD protein that is expressed in a wide variety of cells. CyPA binds the immunosuppressive agent cyclosporin A (hereinafter “CsA”) (Etzkorn et al., Current Biology 3:929-933, 1993; Liu, Immunol Today. 14:290-295, 1993 [published erratum appears in Immunol. Today 14(8):399, 1993]), and possesses a peptidyl-prolyl cis-trans isomerase (PPIase) activity, and protein folding or "chaperone” activities (Galat, Eur. J. Biochem. 216:689-707, 1993; Kofron et al., Biochemistry.
  • CsA immunosuppressive agent cyclosporin A
  • CyPA is a member of the "immunophilin family," that is a group of related cellular factors involved in regulating immunity (Galat, Eur. J. Biochem. 216:689-707, 1993; Fruman et al., FASEB. J. 8:391-400, 1994). At least four types of mammalian cyclophilins have been cloned, CyPA, CyPB, CyPC and hCyP3 (Friedman et al., Proc. Natl. Acad. Sci. USA, 90:6815-6819, 1993).
  • CyPA is recognized to be one of the host cell receptors for CsA, a potent immunosuppressive drug that is widely used in prevention of graft rejection.
  • CsA is a member of a family of hydrophobic cyclic undecapeptides that exhibits potent immunosuppressive, antiparasitic, fungicidal and chronic, anti-inflammatory properties.
  • CsA is thought to exert its immunosuppressive effects by inhibiting the early stages in T cell activation.
  • CsA has been found to block RNA transcription of the T cell growth factor interleukin 2 (IL-2), and to inhibit expression of the IL-2 receptor by precursor cytolytic T lymphocytes (Palacios, J. Immunol. 128:337, 1982).
  • CyPA binds to CsA with a dissociation constant in the range of 10 "8 mol/L, a value consistent with levels needed to elicit immunosuppression (Handschumacher et al., Science 226:544, 1984).
  • CyPA CyPA-binding protein
  • capsid antigen portion thereof A functional association of CyPA with the Gag protein of HIV virions, and specifically with the capsid antigen portion thereof, has been identified (Luban et. al., Cell, 1993). CyPA is specifically incorporated into HIV-1 virions, and disruption of the Gag-cyclophilin interaction has been reported to prevent both incorporation of CyPA into virions, and HIV-1 replication (Franke et al., Nature 372:359-362, 1995; Thali et al., Nature 372:363-365, 1994). These data are consistent with a model whereby the interaction of Gag with CyPA is necessary for the formation of infectious HIV-1 virions (Braaten et. al., J.Virol. 70:3551-3561, 1966).
  • CsA has been shown to interfere with Gag-cyclophilin interactions in vitro, block cyclophilin incorporation into virions, and inhibit the replication of HIV-1 in cell culture (Franke et al., supra; Thali et al., supra; Billich et al., J. Virol. 69:2451-2461, 1995). CsA has not been shown to interact directly with the HIV-1 virus. It is hypothesized that CsA, and its analogs, interfere at two stages in the HIV life cycle.
  • CsA is a potent immunosuppressive agent.
  • its use in HIV-infected patients, who will become immunocompromised, is contraindicated.
  • RA Rheumatoid arthritis
  • RA Rheumatoid arthritis
  • a persistent inflammatory synovitis thought to be initiated by T cell-dependent mechanisms, is one of the hallmarks of RA, and usually affects the peripheral joints as a symmetric polyarthritis (Brooks, supra).
  • This inflammatory synovitis is believed to be exacerbated by (a) infiltrating neutrophils that release oxygen radicals and proteolytic enzymes, and (b) resident fibroblast-like synovial cells which release proenzyme forms of matrix metalloproteinases which are themselves activated by neutrophil proteases and subsequently cause cartilage degradation.
  • synovial inflammation leads to cartilage destruction and bone erosion with subsequent joint deformities (Zvaifler & Firestein, Arthritis Rheum. 37:783-789, 1994; Sewell & Trentham, Lancet 341:283-286, 1993).
  • T Cell Involvement Strong evidence for the role of T cells in the initiation and perpetuation of RA is accumulating, although other cell types (e.g., dendritic cells, fibroblast- like synoviocytes, and primary B cells) contribute to the characteristic progressive joint destruction (Thomas et al., J. Leukoc. Biol. 66:286-292, 1999; McCachren, Arthritis Rheum. 34:1085-1093, 1991; Zvaifler & Firestein, supra).
  • neutrophils, and neutrophil products in joint destruction Edwards & Hallett, Immunol Today 18:320-324, 1997; Harris, supra; Kakimoto et al., Cell Immunol.
  • rheumatoid arthritis is a complex, progressive disease, involving multiple cell types.
  • Therapeutic intervention strategies in RA patients have been primarily directed at blocking the onset and propagation of the disease, and secondarily at blocking local joint inflammation that mediates joint damage and injury (Harris, N. Engl. J. Med. 322:1277-1289, 1990 [published erratum appears inN. Engl. J. Med. 323:996, 1990; see comments]; Brooks, Lancet 341:286-290, 1993).
  • the stimulus for synovial hyperplasia in RA has been classically, described as an immune-mediated inflammatory process (Zvaifler & Firestein, Arthritis Rheum. 37:783-7899, 1994). Such inflammation is believed to be the response to factors made by activated CD4 + T . cells, the predominant cell in the subintimal infiltrates of the RA synovium (Zvaifler & Firestein, Arthritis Rheum. 37:783-7899, 1994; McCachren, Arthritis Rheum. 34:1085-1093, 1991).
  • CsA cyclosporin A
  • Non T Cell Factors in RA Neutrophils and Matrix Metalloproteinases (MMPs).
  • MMPs Matrix Metalloproteinases
  • Neutrophils. RA is characterized by the accumulation of a large number of neutrophils in the synovial fluid.
  • Chemo attractants such as C5a, leukotriene B 4 , platelet activating factor (PAF), and IL-8 (Harris, N. Engl. J. Med. 322:1277-1289, 1990 [published erratum appears in N. Engl. J. Med. 323:996, 1990; see comments]; Edwards & Haliett, Immunol. Today 18:320-324, 1997; Premack & Schall, Nature Med. 2:1174-1178, 1996), are believed to play a role in eliciting the characteristic neutrophil influx.
  • Neutrophils are activated within the joint fluid, most likely by the phagocytosis of cellular debris and immune complexes, resulting in degranulation and release of proteinases and reactive oxidants (Harris, N. Engl. J. Med. 322: 1277-1289, 1990 [published erratum appears in N. Engl. J. Med. 323:996, 1990; see comments]). Additionally, activated neutrophils secrete many of the cytokines that are detectable in RA synovial fluid: IL-l ⁇ , IL-8, IL-12, TNF- ⁇ , TGF-, and GRO- ⁇ (Edwards & Haliett, Immunol. Today 18:320-324, 1997).
  • Neutrophils also play a central role in tissue destruction, most likely because they release enzymes (e.g., elastase), into the joint where they are destructive (Sewell & Trentham, Lancet 341 :283-286, 1993; Edwards & Haliett, Immunol. Today 18:320-324, 1997). Accordingly, blocking neutrophil elastase with specific inhibitors (e.g., MDL 101, 146 and ONO-5046) results in decreases in cartilage destruction in animal models of arthritis (Janusz & Durham, Inflamm.Res. 46:503-508, 1997; Kakimoto et al., Cell Immunol. 165:26-32, 1995).
  • enzymes e.g., elastase
  • specific inhibitors e.g., MDL 101, 146 and ONO-5046
  • Matrix Metalloproteinases comprise a group of structurally related zinc metalloendopeptidases capable of degrading extracellular, matrix components (Nagase et al., Matrix Suppl 1 :237-244, 1992; Giambehap et al., Matrix Biol 16:483-496, 1998). MMPs play an important beneficial role in normal tissue remodeling processes, wherein MMP activities are precisely controlled in various cell types.
  • MMP activity is not only controlled at the level of cellular gene expression, but also at the protein level, either by precursor activation (proMMP to MMP) or inhibition of activated species by endogenous inhibitors, e.g., by ⁇ 2 -macroglobulin and tissue inhibitors of metalloproteinases (TIMPs) (Nagase et al., Matrix Suppl. 1:237-244, 1992; Ogata et al., J. Biol Chem. 270:18506- 18511, 1995; Zucker et al., J. Biol. Chem. 273:1216-1222, 1998).
  • precursor activation proMMP to MMP
  • endogenous inhibitors e.g., by ⁇ 2 -macroglobulin and tissue inhibitors of metalloproteinases (TIMPs) (Nagase et al., Matrix Suppl. 1:237-244, 1992; Ogata et al., J. Biol Chem. 270
  • MMPs contributes to the pathological destruction of the extracellular matrix in many connective tissue diseases such as arthritis, periodontitis, tissue ulceration, and in cancer cell invasion and metastasis
  • connective tissue diseases such as arthritis, periodontitis, tissue ulceration, and in cancer cell invasion and metastasis
  • NSAIDs and slow-acting anti-rheumatic drugs
  • SAARDs slow-acting anti-rheumatic drugs
  • Such combination therapies are often effective, but result in significant side effects.
  • NSAIDs provide significant symptomatic relief of joint inflammation, but can accumulate in kidney and gut leading to adverse reactions, including gastrointestinal distress, renal damage, and skin reactions (Yocum, Semin. Arthritis Rheum. 29:27-35, 1999; Brooks, Lancet 341:286-290, 1993).
  • Cyclophilin A One specific therapeutic target, relevant to all three of the above- mentioned process areas, is cyclophilin A (hereinafter "CyPA") the ubiquitously-distributed host cell receptor for CsA. CyPA is not entirely an intracellular protein, but is also secreted by cells in response to inflammatory stimuli (Sherry et al., Proc. Natl. Acad. Sci. USA 89:3511-3515, 1992). Extracellular CyPA is a potent neutrophil and eosinophil chemoattractant in vitro, and elicits an inflammatory response characterized by a rapid influx of neutrophils when injected in vivo (Sherry et al., Proc. Natl. Acad. Sci.
  • the synovial fluid in the joints of RA patients contains high levels of CyPA, and that such CyPA levels correlate both with the number of neutrophils in the synovial fluid and with disease severity (Billich et al., J. Exp. Med. 185:975-980, 1997). It is logical to presume that the CyPA released into the synovial fluid is attracting neutrophils, which become activated upon arrival and, in turn, release proteolytic enzymes and oxidants that promote cartilage destruction and exacerbate disease. Thus, the effectiveness of CsA in alleviating RA may be manifested in two ways. Firstly, it may act via its ability to interfere with T cell activation and therefore the initiation of the disease process. Secondly, CsA may act by binding to the CyPA released in the joints during periods of active disease, and thereby blocking CyPA's neutrophil chemo-attractant activity.
  • CsA treatment is inherently toxic, resulting in liver destruction, immune suppression and susceptibility to opportunistic infections. These toxic effects are the result of the fact that CsA is membrane permeable and readily enters into all cells.
  • the present invention is based upon the surprising discovery that the previously known extracellular matrix metalloproteinase inducer protein (“EMMPRIN”) [SEQ ID NO:2], also known as CD 147, is a novel cell-surface receptor for cyclophilins (“CyP”).
  • EMMPRIN extracellular matrix metalloproteinase inducer protein
  • the examples and embodiments of the present invention provide for methods of treatment, pharmaceutical compositions, and for screening assays for test compounds having therapeutic activity for indications such as HIV-1 infection, acquired immune deficiency syndrome ("AIDS"), inflammatory and autoimmune disease (e.g., rheumatoid arthritis ("RA"), EAE, ARDS and peridontitis), connective tissue disorders, tumor growth or metastasis or any condition characterized by local or systemic CyP release, synthesis or binding in a patient needing treatment.
  • indications such as HIV-1 infection, acquired immune deficiency syndrome (“AIDS”), inflammatory and autoimmune disease (e.g., rheumatoid arthritis ("RA"), EAE, ARDS and peridontitis), connective tissue disorders, tumor growth or metastasis or any condition characterized by local or systemic CyP release, synthesis or binding in a patient needing treatment.
  • the present invention provides a method for treating or preventing inflammatory disease, autoimmune disease, tissue ulceration, tumor growth or metastasis or any condition characterized by local or systemic CyP release, synthesis or binding in a patient needing treatment, comprising administering to the patient a therapeutically effective amount of a CyP/EMMPRIN antagonist or agonist.
  • the CyP EMMPRIN antagonist or agonist is an anti-EMMPRIN antibody, a soluble EMMPRIN protein or polypeptide, a CyP protein or polypeptide and combinations thereof.
  • the inflammatory or autoimmune disease is arthritis, EAE, ARDS or peridontitis.
  • the CyP/EMMPRIN antagonist or agonist is an anti-EMMPRIN antibody.
  • the anti-EMMPRIN antibody binds to the extracellular domain or the transmembrane domain of EMMPRIN.
  • the anti- EMMPRIN antibody is a monoclonal antibody.
  • the anti-EMMPRIN monoclonal antibody is a single-chain antibody, chimeric antibody, humanized antibody, or Fab fragment.
  • the anti-EMMPRIN antibody binds to an epitope that is recognized by the UM- 8D6 anti-CD 147 monoclonal antibody.
  • the CyP EMMPRIN antagonist or agonist is an EMMPRN polypeptide comprising an amino acid sequence of about 5 to 14 amino acids taken from a sequence extending from about residue 206 to about residue 229 of [SEQ ID NO:2] corresponding to the EMMPRIN transmembrane domain.
  • the present invention further provides a method for treating or preventing inflammatory disease, autoimmune disease, tissue ulceration, tumor growth or metastasis or any condition characterized by local or systemic CyP release, synthesis or binding in a patient needing treatment, comprising administering to the patient a therapeutically effective amount of a compound of forumla I wherein formula I is
  • R x - is His-, SerHis-, ArgSerHis-, Lys-, LysLys-, Arg- or nothing
  • R 2 , R 3 and R 4 are independently Leu, He, Ala, Met or nothing
  • Rj and R 8 are independently Leu, He, Ala or Met
  • s and R 7 are independently Phe, Trp or Tyr
  • -R ⁇ is -Gly, -Glylle, -GlylleVal or nothing.
  • R r is His-, SerHis-, ArgSerHis-, Lys-, LysLys-, Arg- or nothing;
  • R 2 is Leu;
  • R 3 is Ala;
  • R 4 is Ala;
  • R 5 is Leu;
  • R 6 is Trp;
  • R 7 is Phe;
  • R 8 is Leu; and
  • -R is nothing.
  • R is nothing; R 2 is Leu; R 3 is Ala; R 4 is Ala; R 5 is Leu; R 6 is Trp; R 7 is Phe; R 8 is Leu; and -R, is nothing.
  • the present invention further provides a method for decreasing the susceptibility of a cell to retroviral infection, wherein the cell expresses a functional EMMPRIN receptor, and wherein a retrovirus uses the EMMPRIN receptor in a pre-integration step of viral infection, comprising contacting the cell with an amount of a CyP/EMMPRIN antagonist or agonist sufficient to inhibit the pre-integration step of retroviral infection.
  • the CyP/EMMPRIN antagonist or agonist is an anti-EMMPRIN antibody, a soluble EMMPRIN protein or peptide, a CyP derivative or peptide, and combinations thereof.
  • the CyP/EMMPRIN antagonist or agonist is an anti-EMMPRIN antibody.
  • the anti-EMMPRIN antibody binds to the extracellular domain or the transmembrane domain of EMMPRIN.
  • the anti- EMMPRIN antibody is a monoclonal antibody.
  • the anti-EMMPRIN monoclonal antibody is a single-chain antibody, chimeric antibody, humanized antibody, or Fab fragment.
  • the anti-EMMPRIN antibody binds to an epitope that is recognized by the UM- 8D6 anti-CD 147 monoclonal antibody.
  • the CyP/EMMPRIN antagonist or agonist is an EMMPRN polypeptide comprising an amino acid sequence of about 5 to 14 amino acids taken from a sequence extending from about residue 206 to about residue 229 of [SEQ ID NO:2] corresponding to the EMMPRIN transmembrane domain.
  • the present invention further provides a method for decreasing the susceptibility of a cell to retroviral infection, wherein the cell expresses a functional EMMPRIN receptor, and wherein a retrovirus uses the EMMPRIN receptor in a pre-integration step of viral infection, comprising contacting the cell with an amount of a compound of formula I sufficient to inhibit the pre- integration step of retroviral infection, wherein formula I is
  • R r is His-, SerHis-, ArgSerHis-, Lys-, LysLys-, Arg- or nothing
  • R 2 , R 3 and R 4 are independently Leu, He, Ala, Met or nothing
  • It- and R 8 are independently Leu, He, Ala or Met
  • R ⁇ - and R 7 are independently Phe, Trp or Tyr; and -R, is -Gly, -Glylle, -GlylleVal or nothing.
  • R is His-, SerHis-, ArgSerHis-, Lys-, LysLys-, Arg- or nothing;
  • R 2 is
  • R is nothing; R 2 is Leu; R 3 is Ala; R 4 is Ala; R ⁇ is Leu; Rg is Trp; R 7 is Phe; R 8 is Leu; and -R, is nothing.
  • the present invention further provides a method for treating or preventing HIV infection
  • AIDS or AIDS-related disorders in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a CyP/EMMPRIN antagonist or agonist.
  • the CyP EMMPRIN antagonist or agonist is an anti-EMMPRIN antibody, a soluble EMMPRIN protein or peptide, a CyP derivative or peptide, and combinations thereof.
  • CyP/EMMPRIN antagonist or agonist is an anti-EMMPRIN antibody.
  • the anti-EMMPRIN antibody binds to the extracellular domain or the transmembrane domain of EMMPRIN.
  • the anti-EMMPRIN antibody is a monoclonal antibody.
  • the anti-EMMPRIN monoclonal antibody is a single-chain antibody, chimeric antibody, humanized antibody, or Fab fragment.
  • the anti-EMMPRIN antibody binds to an epitope that is recognized by the UM-8D6 anti-CD 147 monoclonal antibody.
  • the present invention further provides a method for treating or preventing HIV infection, AIDS or AIDS-related disorders in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of formula I, wherein formula I is
  • R,- is His-, SerHis-, ArgSerHis-, Lys-, LysLys-, Arg- or nothing
  • R 2 , R 3 and R 4 are independently Leu, He, Ala, Met or nothing
  • It- and R 8 are independently Leu, He, Ala or Met
  • Re and R 7 are independently Phe, Trp or Tyr
  • -Rg is -Gly, -Glylle, -GlylleVal or nothing.
  • R r is His-, SerHis-, ArgSerHis-, Lys-, LysLys-, Arg- or nothing;
  • R 2 is Leu;
  • R 3 is Ala;
  • R 4 is Ala;
  • R s is Leu;
  • R 6 is Trp;
  • R 7 is Phe;
  • R 8 is Leu; and
  • -R is nothing.
  • R r is nothing;
  • the present invention further provides a method for identifying test compounds having therapeutic activity for HIV infection, AIDS or AIDS-related disorders, inflammatory disease, autoimmune disease, tumor growth or metastasis or any condition characterized by local or systemic CyP release, synthesis or binding in a patient needing treatment, comprising: (a) contacting a test compound with a functional CyP protein and a functional EMMPRIN protein wherein at least one of the proteins bears a detectable label; (b) assaying any resulting EMMPRIN/CyP complex for the presence of the label; and (c) determining whether the test compound inhibited binding of the CyP protein to the EMMPRIN protein, whereby test compounds that inhibit binding of the CyP protein to the EMMPRIN protein are identified as therapeutic compounds.
  • either the functional EMMPRIN protein or the functional CyP protein is immobilized onto a solid phase.
  • the CyP protein or the EMMPRIN protein is labeled with a radiolabel, a fluorescent reporter or quencher moiety, an enzymic label that catalyzes a colorometric or fluorometric change or combinations thereof.
  • the inflammatory or autoimmune disease is arthritis, EAE, ARDS or peridontitis.
  • the present invention further provides a method for identifying test compounds having therapeutic activity for HTV infection, AIDS or AIDS-related disorders, inflammatory disease, autoimmune disease, tumor growth or metastasis or any condition characterized by local or systemic CyP release, synthesis or binding in a patient needing treatment, comprising: (a) contacting a test compound, in the presence of a functional CyP protein, with a cell expressing a functional EMMPRIN protein; and (b) determining whether the test compound inhibits binding of the CyP protein to the EMMPRIN protein, whereby test compounds that inhibit binding of the CyP protein to the EMMPRIN protein are identified as therapeutic compounds.
  • the inflammatory or autoimmune disease is arthritis, EAE, ARDS or peridontitis.
  • the cell expresses recombinant EMMPRIN, CD4, CXCR4 or combinations thereof.
  • determination of the inhibition of binding of the CyP protein to the EMMPRIN protein is based on an assay selected from the group consisting of CyP/EMMPRIN antagonist assays, receptor sensitization or desensitization assays, receptor up- or down-regulation assays, EMMPRIN- mediated signal transduction assays, Ca 2+ mobilization assays, matrix metalloproteinase expression or activity assays, cell growth rate assays, HIV-1 infection assays, and assays based on detection of a specific marker of cell cycle or cell differentiation.
  • the EMMPRIN- mediated signal transduction assays are based on determining the phosphorylation or activation status of an intracellular protein, wherein the intracellular protein is selected from the group consisting of Ras, PKA, RAP1, B-Raf, Mek, and MAPK, whereby test compounds that alter the phosphorylation or activation status of said intracellular proteins, relative to their phosphorylation or activation status in control cells, are identified as therapeutic compounds.
  • the specific marker of cell cycle or cell differentiation is selected from the group consisting of cell-cycle regulatory proteins cyclin Dl, cyclin E and p21/Wafl, whereby test compounds that alter said cell-cycle markers, relative to their status in control cells, are identified as cancer therapeutic compounds.
  • the matrix metalloproteinase expression assays measure the expression or activity of proMMP-1, proMMP-3, proMMP-9, MMP-1, MMP-3 or MMP-9.
  • the HIV-1 infection assays measure viral reverse transcriptase activity or virus-directed luciferase expression.
  • compositions comprising a compound of formula I or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier, wherein formula I is
  • R,- is His-, SerHis-, ArgSerHis-, Lys-, LysLys-, Arg- or nothing
  • R 2 , R 3 and R 4 are independently Leu, He, Ala, Met or nothing
  • Rj and R 8 are independently Leu, He, Ala or Met
  • R 6 and R 7 are independently Phe, Trp or Tyr
  • -R ⁇ is -Gly, -Glylle, -GlylleVal or nothing.
  • R is His-, SerHis-, ArgSerHis-, Lys-, LysLys-, Arg- or nothing;
  • R 2 is Leu;
  • R 3 is Ala;
  • R 4 is Ala;
  • R j is Leu;
  • R 6 is Trp;
  • R 7 is Phe;
  • R 8 is Leu;
  • -R ⁇ is nothing.
  • R r is nothing;
  • R 2 is Leu;
  • R 3 is Ala;
  • R 4 is Ala;
  • R 5 is Leu;
  • Rg is Trp;
  • R 7 is Phe;
  • R 8 is Leu; and
  • -Rg is nothing.
  • Figure 1 shows a schematic representation of the human EMMPRIN protein encoded by the cDNA clone isolated according to the present invention [SEQ ID NO: 1 ] .
  • the 269-amino acid EMMPRIN protein is divided into several functional domains, including signal peptide (sp), extracellular domain (ecd), transmembrane domain (tm), and intracellular domain (icd).
  • sp signal peptide
  • ecd extracellular domain
  • tm transmembrane domain
  • icd intracellular domain
  • Both EMM.C1 and EMM.C2 constructs used for binding studies lacked the signal peptide, and one (EMM.C1) had only the extracellular domain.
  • the right right-hand panel of Figure 1 shows that [ 35 S]-labeled EMMPRIN was specifically retained by CyPA-sepharose affinity resin.
  • FIG. 2 shows a FACS analysis of EMMPRIN expression in CHO cells stably transfected with empty vector (CHO), or in an EMMPRIN-expressing CHO cell line (CHO- EMM) EMMPRIN expression was analyzed by FACS using anti-CD147 (M6FT), a commercially-available anti-EMMPRIN antibody (Research Diagnostics, Inc.; Flanders, NJ). CHO cells can be stably transfected to express high levels of EMMPRIN.
  • Figure 3 shows that Ca 2+ mobilization in CHO (no EMMPRIN expression) or CHO-
  • EMM cells stable constitutive EMMPRIN expression
  • CyPA 10 ⁇ g/ml
  • CyPA-induced signaling in CHO-EMM cells was blocked by anti-CD 147 mAb (M6FT) antibody (i.e., anti-EMPRIN mAB), but not by isotype control antibody (right-hand panel).
  • M6FT anti-CD 147 mAb
  • Figure 4 shows that genistein (a tyrosine kinase inhibitor) completely abrogated CyPA- induced, EMMPRIN-mediated Ca 2+ mobilization in CHO-EMM cells.
  • CyPA-induced Ca 2+ mobilization was measured in CHO-EMM cells pretreated with various inhibitors of various kinases known to be involved in the transduction of intracellular signals.
  • the curves show, from upper to lower, pretreatment with no inhibitor, pertussis toxin (PTX) B-oligomer (induces cross- desensitization of chemokine receptors), PTX (inactivates signaling pathways mediated by members of the Gi-Go and Gt-protein family), PD98059 (a MAPK inhibitor), bisindolylmaleimide I (a PKC inhibitor ) and genistein.
  • Genistein completely abrogated CyPA- induced Ca 2+ mobilization in CHO-EMM cells.
  • FIG. 5 shows a Western immunoblot analysis of the effect of CyPA treatment on matrix metalloprotemase (MMP) expression in WI-38 human primary lung fibroblasts.
  • MMP matrix metalloprotemase
  • Figure 6 shows analyses of luciferase (left-hand and middle panels) and HIV-1 reverse transcriptase activity (right-hand panel) demonstrating that cell-surface EMMPRIN expression enhances MuLV- and HIV-l LAV -pseudotyped HIV-1 (Luc-HIV-1) infection of CHO-EMMPRIN (CHO-EMM) cells relative to CHO (control) cells, that the enhancing effect is greatly reduced by anti-CD147 mAb (UM-8D6), and that the enhancing effect is manifested at a stage preceding integration ofthe proviral DNA.
  • the left-hand panel shows luciferase expression (measured on day 4 post-infection, and expressed as a percentage relative to control) in CHO (control) or CHO-EMM (constitutively expressing EMMPRIN) cells that were infected with luciferaSe-expressing MuLV-pseudotyped HIV-1.
  • control control
  • CHO-EMM constitutitutively expressing EMMPRIN
  • the middle panel shows luciferase expression in triplicate cultures of CHO or CHO- EMM cells that were transiently transfected with CD4- and CXCR-expressing vectors and then infected with Luc-HFV-1, which is pseudotyped with Env derived from HIV-1 LAV that depends on CD4 and CXCR4 for entry. Luciferase expression is presented as percentage of expression relative to control (CHO/CD4/CXCR4 cells; taken as 100%). A 3- to 4-fold increase in luciferase expression was observed in cells expressing EMMPRIN.
  • the right-hand panel shows reverse transcriptase activity in CHO and CHO-EMM cells that were transiently transfected with CD4- and CXCR4-expressing vectors, and then infected with either Env 1 " 1 ⁇ - or Env ⁇ -pseudotyped luc-HIV-1 in the presence of anti-CD 147 mAb (UM- 8D6) or isotype-matched irrelevant antibody.
  • Viral DNA was analyzed by PCR 2 hr after infection using primers LTR R/U5 specific for the early reverse transcription products.
  • Results were quantified on a Direct Imager (Packard) and are presented as radioactivity associated with LTR/g ⁇ g-specific signal relative to control (isotype-treated CHO/CD4/CXCR4 cells; taken as 100%).
  • the amount of LTR R/U5 reverse transcription product following infection with Env MuLV and Env ⁇ -pseudotyped viruses was increased 3- to 4-fold in CHO-EMM/CD4/CXCR4 cells compared to CHO/CD4/CXCR4 cells.
  • anti-CD 147 mAb diminished the enhancing effect of EMMPRIN.
  • Figure 7 A shows that anti-CD 147 mAb inhibited HIV-1 replication in human primary PBMC.
  • Triplicate cultures of PHA-activated PBMC were infected with either the T- lymphotropic X4 strain HIV-1 LAV or the macrophage-tropic R5 HIV-1 ADA (left-hand panel), or with luciferase-expressing recombinant HIV-1 pseudotyped with envelopes derived from LAV or ADA strains (right-hand panel).
  • Anti-CD 147 mAb (UM-8D6) or isotype-matched control mAb were added 30 min. prior to infection and were present throughout the duration of the experiment.
  • Virus replication was assessed by RT activity in culture supernatants on day 21 (left-hand panel), or by luciferase activity on day 4 after infection (right-hand panel). Results are presented as RT or luciferase activity relative to control (cells treated with isotype-matched irrelevant mAb; taken as 100%). The results show that EMMPRIN was involved in HIV-1 infection.
  • Figure 7B shows that anti-CD 147 mAb did not block HIV attachment to human PBMC.
  • Triplicate PBMC cultures were pre-treated at 37°C with anti-CD 147 mAb (UM-8D6; at 50 ⁇ g/ml), anti-CD4 mAb (5 ⁇ g/ml), or heparinase III (3X10 "4 IU/ml), and then washed and incubated with HIV-1 LAV (10 ng/ml of p24) at 4°C for 1 hr. The amount of cell-bound viral p24 was assayed by ELISA. The results shown are for one representative experiment out of three performed with PBMC from different donors.
  • Anti-CD 147 mAb did not block HIV- 1 L ⁇ V attachment to human PBMC, whereas anti-CD4 mAb significantly reduced attachment.
  • Figure 7C shows that anti-CD 147 mAb neither blocked HIV Env-mediated fusion between PBMC and HeLa cells expressing HIV-1 ADA and LAV envelopes, nor reduced cellular internalization of viral p24.
  • Fusion between PBMC and HeLa cells expressing HTV-1 Env was assessed in the presence of anti-CD147 (UM- 8D6; at 50 ⁇ g/ml) or anti-CD4 (5 ⁇ g/ml) mAb by ⁇ -Gal expression (see “Methods," Example 6).
  • Results are expressed as ⁇ -Gal activity relative to positive control (untreated cells; taken as 100%), and are presented as mean ⁇ SD of three independent measurements with cells from the same donor.
  • Right panel For analysis of virus-cell fusion, PBMC were incubated with HTV- 1 LAV (see “Methods," Example 6). Cells were then treated with trypsin (0.025% for 30 min. at 37°C), lysed, and viral p24 was measured in the lysates by ELISA. These data show that the inhibitory effect of anti-CD 147 mAb (UM-8D6) on HIV-1 infection was mediated by a post- fusion mechanism.
  • U-8D6 anti-CD 147 mAb
  • Figure 7D shows that anti-CD 147 mAb reduced the amount of HIV-1 reverse transcription.
  • Analysis of HIV-1 reverse transcription was performed 2 hr after infection of the PBMCs with HIV-1 LAV , using LTR R/U5 primers specific for the "strong-stop" early reverse transcription products.
  • PCR results were quantified on a Direct Imager (Packard) and are presented as percentage of counts in treated, relative to antibody-untreated control (taken as 100%).
  • the anti- CD 147 mAb (UM-8D6) reduced the amount of the reverse transcription product by approximately 2-fold.
  • anti-CD4 mAb reduced the amount of LTR R/U5-amplified fragment even more dramatically.
  • Lower-left panel Dilutions of 8E5/LAI cells containing one HTV-1 genome per cell were used as PCR standards.
  • Figure 7E shows the effect of anti-CD 147 mAb on subcellular distribution of HIV- 1 proteins.
  • MT-4 cells were inoculated at 4°C with HIV-1 LAI in the presence of 50 ⁇ g/ml of anti- CD147 mAb (Ancell) or isotype-matched control mAb.
  • An aliquot (lxlO 6 cells) was withdrawn after 30 minutes for protein analysis (i.e., the 0 hr p.i. time-point sample) (upper panel), while the inoculated cultures were transferred to 37°C and incubated for 1.5 hr (lower panels).
  • Subcellular fractionation was performed (see “Methods,” Example 6) and proteins in cytosolic (C), membrane (M), and cytoskeleton (CS) fractions were analyzed by Western blot and ECL using monoclonal antibodies to actin, CA, and MA.
  • Viral MA protein and CA in the absence of anti-CD 147 mAb, underwent characteristic translocations from the membrane (M), into the cytoskeleton (CS), and cytosol fractions, respectively, 1.5 hours after infection (isotype panel, lanes "CS" and "C,” respectively).
  • Virus-producing transfected cells were washed and cultured in quadruplicate for additional 4 days with (“293T + CD4 + T cells") or without ("293T”) addition of CD8 + T cell-depleted PBMC and anti-CD147 mAb (UM-8D6; at 100 ⁇ g/ml). Virus replication was assayed by measuring RT activity in culture supernatants. Results are presented as mean ⁇ SE. Anti-CD 147 mAb (UM-8D6) did not inhibit replication of the CsA-resistant A224E virus, whereas replication of the wild-type virus was significantly diminished.
  • Figure 9 shows that an eight-amino acid polypeptide ([SEQ ID NO:3]) from the amino- terminal end of the EMMPRIN transmembrane region blocked infection of CHO-EMM cells by Env- ⁇ - ⁇ -pseudotyped luciferase-expressing HTV-1.
  • the right-hand panel shows luciferase expression data on day 4 post-infection of CHO and CHO-EMM cells that were infected with recombinant Env MuLV - pseudotyped luciferase-expressing HIV-1 in the presence of the indicated concentrations of peptides 1, 2 and "scrambled peptide 1."
  • Peptide 1 (LAALWPFL) is an eight-amino acid sequence [SEQ ID NO:3] corresponding to amino acids 206-213 of the EMMPRIN transmembrane domain.
  • Peptide 2 (GTVAEVLVL) is a nine-amino acid polypeptide sequence [SEQ ID NO:4] corresponding to amino acids 214-222 of the EMMPRIN transmembrane domain.
  • Scrambled peptide 1 (FAWPLLLA), the randomized sequence control, was made according to a randomized sequence of the amino acid residues of peptide 1.
  • CyP refers to the protein cyclophilin of which at least four types are known, CyPA (the host-cell receptor for cyclosporin A), CyPB, CyPC and hCyP3, any derivative of cyclophilin, or any fragments or peptides having an amino acid sequence corresponding to cyclophilin.
  • Polypeptides or peptide fragments of CyP are referred to as CyP polypeptides or CyP peptides, and include derivatives of CyP, CyP polypeptides or peptide fragments, and fusions of CyP, CyP polypeptides or peptide fragments to an unrelated protein (referred to herein as CyP derivatives, and CyP fusion proteins, respectively).
  • a functional CyP refers to a protein that binds to its cognate CyP-binding protein or ligand in vivo or in vitro.
  • a functional CyPA is a CyPA protein, peptide, polypeptide or fusion protein that binds to EMMPRIN, CsA, HTV-gag protein (specifically, with the capsid antigen portion thereof), or combinations thereof.
  • CyP binding protein means any cellular binding protein, cell-surface binding protein or receptor, extracellular receptor, soluble receptor or intracellular binding protein, which has cyclophilin-specific binding activity.
  • EMMPRIN is a cell- surface CyP-binding protein (i.e., a cell-surface receptor for CyP).
  • CsA is cyclosporin A, any derivative of cyclosporin A, or any fragments or peptides having an amino acid sequence corresponding to cyclosporin A.
  • EMMPRTN [SEQ ID NO:2] is the human extracellular matrix metalloproteinase inducer protein, and is a cell-surface CyPA or CyPB receptor.
  • EMMPRIN is alternately referred to in the art as CD 147, basigin and M6-antigen.
  • EMMPRIN polypeptides or EMMPRIN peptides include derivatives of EMMPRIN, EMMPRIN polypeptides or peptide fragments, and fusions of EMMPRIN, EMMPRIN polypeptides or peptide fragments to an unrelated protein (referred to herein as
  • EMMPRIN derivatives and EMMPRIN fusion proteins, respectively).
  • a functional EMMPRIN protein, peptide, polypeptide or fusion protein refers to an EMMPRIN protein, peptide, polypeptide, fusion protein, cellular receptor, soluble receptor or intracellular binding protein that binds CyP protein, peptides or derivatives thereof, or that binds retroviral-associated CyPA proteins or peptides in vivo or in vitro.
  • CD147 means EMMPRIN [SEQ ID NO:2].
  • Anti-EMMPRIN antibody means an anti-CD 147 antibody.
  • Anti-CD 147 or anti-EMMPRIN antibody means an antibody that specifically recognizes one or more epitopes of EMMPRIN, or conserved variants of EMMPRIN or peptide fragments of EMMPRTN, including but not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single-chain antibodies, Fab fragments, F(ab') 2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
  • Anti-CD147 mAb (UM-8D6), or UM-8D6 anti-CD147 monoclonal antibody specifically refers to the murine IgGl anti-CD 147 monoclonal antibody that is commercially available from Ancell Immunology Research Products (Bayport, MN). This antibody was used in Examples 5- 7 below.
  • Anti-CD 147 mAB specifically refers to the anti-CD 147 monoclonal antibody RDI-CD147-M6FT, that is commercially available from, Research Diagnostic, Inc. ("RDI,” Flanders, NJ). This antibody was used in Example 2 below.
  • MMPs means matrix metalloproteinases.
  • ProMMP means the inactive zymogen (proenzyme) form of the corresponding MMP that can be activated by proteolytic cleavage.
  • MMP-1 is produced by proteolytic cleavage of proMMP-1.
  • PIC means HTV-1 pre-integration complex.
  • MA means the HIV-1 matrix antigen protein.
  • CA means the HTV-1 capsid antigen protein.
  • PHA means the phytohaemaglutinin antigen.
  • 293T cells refer to the art-recognized, HTV-1 -susceptible human embryonic kidney cell line.
  • CHO cells refer to the art-recognized Chinese Hamster ovary cell line.
  • CHO-EMM cells refer to the stably-transfected CHO cell line that constitutively expresses high levels of EMMPRIN.
  • MT-4 cells refer to the art-recognized human T cell line.
  • PBMC refers to primary human peripheral blood mononuclear cells.
  • A224E refers to the art-recognized CsA-resistant HTV-1 CA mutant strain.
  • the present invention is based on applicant's surprising discovery of a ligand/receptor relationship between cyclophilin ("CyP”) and extracellular matrix metalloproteinase inducer (“EMMPRIN”).
  • CyP cyclophilin
  • EMMPRIN extracellular matrix metalloproteinase inducer
  • the present invention provides screening methods (e.g., assays) to identify test compounds that modify the CyP/EMMPRIN interaction, and that thereby have therapeutic utility in methods of treatment for indications such as HIV-1 infection, acquired immune deficiency syndrome ("AIDS"), inflammatory and autoimmune disease (e.g., rheumatoid arthritis ("RA"), EAE, ARDS, peridontitis), tumor growth or metastasis or any condition characterized by local or systemic CyPA release, synthesis or binding in a patient needing treatment.
  • Compounds encompassed by the methods of present invention include, small molecules, large molecules (e.g., EMMPRIN or CyP proteins, and peptides thereof) and antibodies.
  • Cellular and non-cellular assays can be used to identify compounds that interact with EMMPRIN, and/or CyP, to mimic, modulate or antagonize association between these molecules, and/or to modulate the activity of EMMPRIN, CyP, or the EMMPPJN:CyP complex.
  • the cell- based assays can be used to identify compounds or compositions that affect, e.g., the activity, translocation, or cellular compartmentalization of EMMPRTN, CyP, or the EMMPRTN:CyP complex, or the EMMPRIN-mediated cellular compartmentalization of other proteins (e.g., HIV- 1 MA and CA proteins).
  • the assays can measure, among other parameters, direct binding to EMMPRIN, CyP, or the EMMPRIN:CyP complex , or can measure indirect effects on or by intracellular factors involved in the downstream signal transduction pathway.
  • Such cell-based assays utilize cells, cell lines, or engineered cells or cell lines that express EMMPRIN and/or
  • CyP proteins or peptides, or fusions thereof with unrelated proteins or peptides can be further engineered to incorporate a reporter molecule linked to the signal transduced by EMMPRTN, CyP, or the EMMPRTN:CyP complex to aid in the identification of compounds that modulate EMMPRTN-mediated signaling activity.
  • EMMPRIN and CyP proteins, polypeptides and fusion proteins are used in cell, and non- cell based assays for screening compounds that interact with, and or modulate the activity of EMMPRTN, CyP, or the EMMPRrN:CyP complex, for generating antibodies, and for diagnostics and therapeutics.
  • EMMPRIN or CyP protein products are used therapeutically as EMMPRIN antagonists or agonists.
  • Such EMMPRIN or CyP protein products include, but are not limited to peptides or polypeptides corresponding to one or more EMMPRIN or CyP domains (e.g., the EMMPRIN- interaction domain of CyP), truncated EMMPR ⁇ N or CyP polypeptides lacking one or more EMMPR ⁇ N or CyP domains (e.g., in the case of EMMPRTN, the extracellular and/or the transmembrane domains, etc.), EMMPRIN or CyP fusion protein products (e.g., GST fusions, or epitope tagged fusions, including EGFP and FLAG fusions), and EMMPRIN or CyP protein or peptide derivatives or complexes.
  • EMMPRIN or CyP protein products include, but are not limited to peptides or polypeptides corresponding to one or more EMMPRIN or CyP domain
  • an effective amount of an appropriate soluble EMMPRTN protein or peptide, or a EMMPRTN fusion protein is administered to a patient, whereby it interacts with and alternatively “activates,” “neutralizes,” or “mops up” endogenous CyP, to modulate the activity of EMMPRIN, CyP, or the EMMPRTN:CyP complex.
  • nucleotide constructs encoding such EMMPRIN products are used to genetically engineer host cells to express such EMMPRIN products in vivo. These genetically engineered cells function as "bioreactors" in the body, delivering a continuous supply of the appropriate soluble EMMPRIN product that will alternatively “activate,” “neutralize,” or “mop up” endogenous CyP.
  • antibodies to EMMPRIN or other agents that are EMMPRIN agonists or antagonists, and/or that modulate EMMPRIN-mediated signal transduction, and that act on downstream targets in the EMMPRIN-mediated signal transduction pathway are used as therapeutic agents.
  • CyP EMMPRIN Binding Interaction is a Novel Therapeutic Intervention Target for Conditions Characterized by Local or Systemic CyP Release, Synthesis or Binding such as Rheumatoid Arthritis (RA)
  • the CyP/EMMPRIN binding interaction is a novel intervention target for CyPA-related therapeutic indications such as RA because: (1) EMMPRIN is a CyP binding protein; (2) EMMPRTN is a signaling receptor for CyP, and mediates tyrosine kinase-dependant signal transduction; and (3) CyP treatment activates and enhances expression and release of proMMP-1 and proMMP-3 in WI-38 primary human fibroblasts.
  • EMMPRIN was identified as a CyPA binding-protein. Specifically, an EMMPRIN cDNA clone [SEQ ID NO:l] was isolated and initially identified as a CyPA interacting protein by a standard Yeast Two-Hybrid protocol (Example 1 and Figure 1). The CyPA/EMMPRIN binding interaction was then confirmed by demonstrating specific binding of [ 35 S]-labeled EMMPRTN to CyPA sepharose affinity resin (Example 1, Figure 1, right-hand panel).
  • EMMPRIN was identified as a signaling receptor for CyP, and mediated tyrosine kinase-dependant signal transduction.
  • CyPA or CyPB induced Ca 2+ mobilization in CHO-EMM cells (that are stably transfected with an EMMPRrN-expression vector, and that constitutively express EMMPRIN), but not in control CHO cells (no EMMPRTN expression) (Example 2, and Figure 3, left-hand panel).
  • anti-CD147 mAb i.e., anti- EMMPRIN mAb
  • isotype control antibody blocked CyPA-mediated Ca 2+ mobilization in CHO-EMM cells ( Figure 3, right-hand panel).
  • EMMPRIN was identified as a cellular receptor for CyPA and CyPB, and mediated intracellular signal transduction through a tyrosine kinase-dependant pathway.
  • CyPA treatment activated expression ofproMMP-1, and enhanced release of proMMP-3 in WI-38 primary human fibroblasts.
  • Treatment of WI-38 primary human fibroblasts with CyPA activated expression and release of the metalloproteinase zymogen proMMP-1, and enhanced the release of proMMP-3 (Example 4 and Figure 5).
  • Metalloproteinases MMP-1 and MMP-3 are known to be elevated in the synovial fluid of RA patients, and are believed to contribute to RA disease-related pathology.
  • Active MMP-1 and MMP-3 species are processed from the corresponding secreted inactive zymogens, proMMP-1 and proMMP-3 by proteolytic enzymes normally released by surrounding tissue (e.g., the proteolytic enzymes in synovial joint fluid of RA patients).
  • EMMPRIN stimulates MMP production is more complex than that presented by earlier references that narrowly characterize EMMPRTN as an adhesion-type molecule involved in cell-cell interactions.
  • EMMPRIN was also identified (as disclosed herein) as a signal transducing receptor that stimulated MMP production by receiving signals via its soluble ligand, CyPA.
  • the present invention supports a model whereby CyP released into inflammed joints during active RA disease attracts neutrophils to the joints via CyP binding to EMMPRIN on neutrophil surfaces. These neutrophils are then activated in the joints via CyP- dependent, and CyP-independent mechanisms to release enzymes (e.g., neutrophil elastase) that exacerbate RA disease. Therefore, anti-EMMPRIN antibodies or other agents that act as EMMPRTN agonists or antagonists have therapeutic utility for the treatment or prevention of RA or other conditions characterized by local or systemic CyP release, synthesis or binding (i.e., CyP-related therapeutic indications).
  • the CyP/EMMPRIN Binding Interaction is a Novel Therapeutic Intervention Target for Conditions Characterized by Local or Systemic CyP Release, Synthesis or Binding such as Treatment or Prevention of HIV-1 Infection and or AIDS or AIDS-related Disorders
  • the CyPA/EMMPRIN binding interaction is a novel intervention target for HIV infection and/or AIDS or AIDS-related disorders because: (1) cell-surface EMMPRIN has a substantial enhancing effect on a pre-integration step of cellular infection of CHO cells by MuLV-, and HTV-1 -pseudotyped retroviruses carrying the HIV-1 core; (2) cell-surface EMMPRTN has a substantial enhancing effect on a pre-integration step of HTV infection of primary human cells (peripheral blood mononuclear cells; PBMC); and (3) viral resistance to the inhibitory effect of anti-CD 147 mAb (UM-8D6) correlates with resistance to CsA.
  • PBMC peripheral blood mononuclear cells
  • EMMPRIN had a substantial enhancing effect on a pre-integration step of cellular infection of CHO cells by MuL V-, and HIV-1 -pseudotyped retroviruses carrying the HIV-1 core.
  • the presence of EMMPRIN protein on the cell surface of CHO cells enhanced infection by MuLV-pseudotyped HTV (Example 5 and Figure 6, left-hand panel).
  • this enhancement was greatly reduced by anti-CD 147 mAb (UM-8D6) (Example 5 and Figure 6, left-hand panel), and such infection was blocked by EMMPRIN transmembrane domain peptide 1 [SEQ ID NO:3] (Example 8 and Figure 9).
  • EMMPRIN enhanced CHO/CD4/CXCR4 cell (CHO cells transfected with CD4- and CXCR4-expressing vectors) infection by HTV-1 pseudotyped HTV (Example 5 and Figure 6, middle panel). Moreover, infection of PHA-activated human PBMC by Env ADA - pseudotyped luc-HTV-1 was blocked by peptide 1 [SEQ ID NO:3] (Example 8). Finally, EMMPRIN enhanced HIV infection at a stage preceding viral integration.
  • HIV-specific reverse transcription increased by 3- to 4-fold in the presence of EMMPRTN (i.e., in CHO-EMM/CD4/CXCR4, compared to CHO/CD4/CXCR4 cells).
  • EMMPRTN i.e., in CHO-EMM/CD4/CXCR4, compared to CHO/CD4/CXCR4 cells.
  • anti-CD 147 mAb diminished this enhancing effect of EMMPRIN ( Figure 6, right- hand panel), indicating that EMMPRIN acts a stage preceding viral integration.
  • Cell-surface EMMPRIN had a substantial enhancing effect on a post-fusion, pre- integration step of HIT infection of PBMC.
  • Anti-EMMPRIN mAb (UM-8D6) inhibited replication of HTV-1 strains in human primary PBMC (Example 6 and Figure 7 A).
  • anti-CD 147 mAb (UM-8D6), but not isotype-matched control mAb, inhibited replication of macrophage-tropic (ADA) and T cell line-adapted (LAV) HIV-1 strains in primary PBMC (Example 6 and Figure 7A, left-hand and right-hand panels).
  • anti-CD 147 mAb (UM-8D6), in contrast to anti-CD4 mAb, did not block HIV attachment to human PBMC, as determined by measuring the amount of cell-bound viral p24 after incubation of the PBMC with HTV-1 at 4°C (Example 6 and Figure 7B). Therefore, anti-CD 147 mAb (UM-8D6) blocked HIV-1 infection at a step between viral attachment and integration.
  • anti-CD 147 mAb (UM-8D6), in contrast to anti-CD4 mAb, neither blocked HIV Env-mediated fusion between PBMC and HeLa cells expressing HIV-1 ADA and LAV envelopes (Example 6 and Figure 7C, left-hand panel), nor reduced cellular internalization of viral p24 (Example 6 and Figure 7C, left panel). Therefore, according to the present invention, EMMPRIN acts at a post-fusion step in HIV-1 infection.
  • anti CD 147 mAb (UM-8D6) reduced the amount of both early and late HIV-1 reverse transcription during HIV-1 infection (Example 6 and Figure 7D). HIV-1 reverse transcription is a post-fusion process that is representative of the progressive maturation of the pre-integration complex ("PIC"). Therefore, anti-CD 147 mAb (UM-8D6) interfered with a step in HIV-1 infection between virus-cell fusion and initiation of reverse transcription.
  • anti-CD 147 mAb (UM-8D6) blocked normal translocation of HTV-1 matrix (MA) and capsid (CA) proteins early after de novo infection. Specifically, in the presence of anti-CD 147 mAb (UM-8D6), virus was retained at the cell membrane, indicating that EMMPRIN plays a role in HTV-1 uncoating (Example 6 and Figure 7E).
  • CyPA mediates HIV-1 infection
  • the mechanism by which CyPA mediates HIV-1 infection is more complex than that presented by the prior-art, which narrowly characterizes CyPA as a protein that interacts with HTV-gag protein in virions, and with cell- surface heparans (asserted, prior to the present invention, to be the "exclusive CyPA receptor"; Saphire et al., EMBOJ. 18:6771-6785, 1999).
  • EMMPRIN mediated a CyPA-dependent step in HTV-1 infection. CyPA was thus involved in multiple interactions with HIV-gag, heparans and EMMPRTN during HTV-1 infection.
  • EMMPRIN mediated a CyPA-dependent step in HTV-1 infection. CyPA was thus involved in multiple interactions with HIV-gag, heparans and EMMPRTN during HTV-1 infection.
  • EMMPRIN mediated the normal translocation of HTV-1 MA and CA proteins early after de novo infection.
  • Demonstration that anti-CD 147 mAb (UM-8D6) antagonized the novel CyPA EMMPRIN binding interaction (and the signal transduction mediated thereby) further enables the use of other agents that modify this interaction for use in methods for the treatment or prevention of HTV-1 infection and/or AIDS, and/or other conditions characterized by local or systemic CyPA release or synthesis (i.e., CyPA-related therapeutic indications).
  • CyP/EMMPRIN Binding Interaction is a Novel Therapeutic Intervention Target for Conditions Characterized by Local or Systemic CyP Release, Synthesis or Binding such as Cancer
  • the CyPA/EMMPRIN binding interaction is a novel intervention target for cancer because: (1) EMMPRTN-expressing tumor cells have been shown to up-regulate the expression of MMPs in fibroblasts co-cultured therewith (Biswas et al., Cancer Res. 55:434-439, 1995); (2) CyP activated and or enhances MMP production in human fibroblasts, as disclosed herein; and (3) the deregulated action of MMPs-contributes to the pathological destruction of the extracellular matrix in many connective tissue diseases including, e.g., arthritis, periodontitis, tissue ulceration, and in cancer cell invasion and metastasis (Kahariet al., Exp.
  • EMMPRIN or CyP protein and polypeptides can be prepared for a variety of uses, including but not limited to the generation of antibodies, as reagents in diagnostic assays, as reagents in assays for screening for therapeutic compounds that can be used in the treatment or prevention of, e.g., HIV-1 infection, ADDS, RA and cancer, and as pharmaceutical reagents useful in the treatment of, e.g., HIV-1 infection, AIDS and AIDS-related disorders, RA and cancer.
  • EMMPRIN and CyP Proteins and Polypeptides The cDNA sequence encoding EMMPRIN is shown in [SEQ ID NO:l], along with the corresponding deduced amino acid sequence [SEQ ID NO:2].
  • Figure 1 shows schematically the signal peptide, extracellular (ecd), transmembrane (tm) and intracellular (icd) domains of EMMPRIN.
  • EMMPRTN e.g., the EMMPRIN ecd or tm domains
  • CyP truncated or deleted EMMPRTN or CyP
  • fusion proteins in which the full-length EMMPRTN or CyP, a EMMPRIN or CyP peptide or truncated EMMPRTN or CyP is fused to an unrelated protein
  • GST e.g., GST, FLAG and EGFP fusions
  • such soluble EMMPRIN proteins, peptides or fusion proteins, or antibodies (including anti-idiotypic antibodies) that bind to and "activate,” “neutralize” or “mop- up” circulating CyP can be used as described herein to treat or prevent, e.g., HTV-1 infection, AIDS, RA and cancer.
  • peptides corresponding to individual domains of EMMPRTN, soluble deletion mutants of EMMPRIN, or the entire EMMPRIN protein can be fused to another polypeptide (e.g., an IgFc polypeptide, or epitope tag).
  • CyP proteins, peptides or fusion proteins that act as agonists or antagonists of the EMMPRTN receptor can be used as described herein to treat or prevent, e.g., HTV-1 infection, AIDS and AIDS-related disorders, RA and cancer.
  • Such peptides, polypeptides, and fusion proteins can be prepared by recombinant DNA techniques.
  • nucleotide sequences encoding one or more EMMPRIN regions or domains can be synthesized or cloned and ligated together to encode a soluble EMMPRTN protein, such as a soluble receptor or soluble binding protein or peptide (e.g., [SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5]).
  • the DNA sequence encoding one or more EMMPRTN regions or domains can be ligated together directly or via a linker oligonucleotide that encodes a peptide spacer.
  • Such linkers may encode flexible, glycine-rich amino acid sequences thereby allowing the domains that are strung together to assume a conformation that can bind EMMPRTN ligands (e.g., CyPA or CyPB).
  • EMMPRTN ligands e.g., CyPA or CyPB
  • nucleotide sequences encoding individual regions or domains can be used to express EMMPRTN peptides. Similar constructions can be prepared using nucleotide sequences encoding one or more CyP regions or domains.
  • a variety of host-expression vector systems may be utilized to express nucleotide sequences encoding the appropriate regions of EMMPRTN or CyP to produce such polypeptides. Where the resulting peptide or polypeptide is a soluble derivative the peptide, the polypeptide can be recovered from the culture media. Where the polypeptide or protein is not secreted, the EMMPRTN or CyP product can be recovered from the host cell itself.
  • the host-expression vector systems also encompass engineered host cells that express EMMPRTN or CyP or functional equivalents. Purification or enrichment of EMMPRTN or CyP proteins, peptides and fusion proteins from such expression systems can be accomplished using appropriate methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of the EMMPRTN or CyP proteins, peptides and fusion proteins, but also to assess biological activity, e.g., in drug screening assays.
  • the host-expression vector systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing EMMPRTN or CyP nucleotide sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing EMMPRTN or CyP nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing EMMPRIN or CyP sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing EMMPRTN or CyP nucleotide sequences;
  • a number of expression vectors may be advantageously selected depending upon the use intended for the EMMPRIN or CyP gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of EMMPRIN or CyP proteins, peptides and fusion proteins, or for raising antibodies to the EMMPRIN or CyP protein, vectors that direct, the expression of high levels of fusion protein products that are readily purified may be desirable.
  • Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., EMBO J.
  • EMMPRIN or CyPA coding sequence may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced;
  • pEST vectors Inouye & Inouye, Nucleic Acids Res. 13:3101-3109, 1985; Van Heeke & Schuster, J. Biol. Chem. 264: 5503-5509, 1989; and the like.
  • PGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST).
  • fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione.
  • the PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
  • a vaccinia expression/affinity purification system allows for the facile expression and purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, et al., Proc. Natl Acad. Sci. USA 88:8972-8976, 1991).
  • the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues.
  • Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni 2+ :nitriloacetic acid-agarose columns and histidine- tagged proteins are selectively eluted with imidazole-containing buffers.
  • Insect systems Autographa californica nuclear polyhedrosis virus (AcNPV) can be used as a vector to express foreign genes in an insect system. The virus grows in Spodoptera frugiperda cells.
  • the EMMPRIN- or CyP-coding sequence may be cloned individually into non- essential regions (e.g., the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (e.g., the polyhedrin promoter).
  • EMMPRTN- or CyP-coding sequence Successful insertion of EMMPRTN- or CyP-coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene).
  • the recombinant viruses are then used to infect cells in which the inserted gene is expressed (Smith et al., J. Virol. 46:584, 1983; Smith, U.S. Patent No. 4,215,051).
  • a number of viral-based expression systems may be utilized.
  • the EMMPRTN or CyP nucleotide sequence of interest may be ligated to an adenovirus transcription translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination.
  • Insertion in a non-essential region of the viral genome will result in a recombinant virus that is viable and capable of expressing the EMMPRIN or CyP gene product in infected hosts (Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:3655-3659, 1984).
  • Specific initiation signals may also be required for efficient translation of inserted EMMPRIN or CyP nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire EMMPRIN or CyP gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed.
  • exogenous translational control signals including, perhaps, the ATG initiation codon, must be provided.
  • the initiation codon must be "in frame” with the reading frame of the desired coding sequence to ensure translation of the entire insert.
  • exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (Bittner et al., Methods Enzymol. 153:516-544, 1987).
  • a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.
  • Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. Accordingly, eukaryotic host cells that possess cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, MCF-7, Hs578T and WI38 cell lines.
  • cell lines that stably express EMMPRTN or CyP sequences may be engineered.
  • host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable, marker.
  • appropriate expression control elements e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.
  • engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.
  • the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci that in turn can be cloned and expanded into cell lines.
  • This method may advantageously be used to engineer stable cell lines that express the EMMPRTN or CyP gene product (e.g., the CHO-EMM cell line discussed in Example 2 below).
  • Such engineered cell lines may be particularly useful in screening and evaluating compounds that affect the endogenous activity of the EMMPRIN gene product.
  • a number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:2026, 1962), and adenine phosphoribosyltransferase (Low, et al., Cell 22:817, 1980) genes can be employed in tk " , hgprt " or aprt " cells, respectively.
  • anti-metabolite resistance can be used as the basis of selection for the following genes: dhfr, that confers resistance to methotrexate (Wigler et al., Proc. Natl. Acad. Sci. USA 77:3567, 1980; O ⁇ are et al., Proc. Natl Acad. Sci. USA 78:1527, 1981); gpt, that confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072, 1981); neo, that confers resistance to the aminoglycoside G-418 (Colberre- Garapin et al., J Mol. Biol. 150:1, 1981); and hygro, that confers resistance to hygromycin (Santerre et al., Gene 30:147, 1984).
  • Antibodies to EMMPRIN or CyPA Polypeptides are also encompassed by the invention.
  • Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single-chain antibodies, Fab fragments, F(ab') 2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope- binding fragments of any of the above.
  • Such antibodies are used as a method for the modulation of normal or abnormal EMMPRIN activity (see Examples 2, 5, 6 and 7), and are therefore useful as part of methods for the treatment and or prevention of, e.g., HTV-1 infection, AIDS, RA and cancer.
  • the antibodies of the invention are used, for example, in the detection of EMMPRIN in a biological sample and are, therefore, useful as part of a diagnostic or prognostic technique whereby patients or tissue samples may be tested for abnormal amounts of EMMPRIN.
  • Such antibodies are also utilized in conjunction with, for example, compound screening schemes for the evaluation of the effect of test compounds on expression and/or activity of the EMMPRIN gene product.
  • such antibodies can be used in conjunction with the gene therapy techniques described, below, e.g., to evaluate the normal and/or engineered EMMPRIN- or CyP-expressing cells prior to their introduction into the patient.
  • EMMPRIN or CyP e.g., one corresponding to a functional domain of EMMPRIN or CyP, such as the transmembrane, extracellular or CyP-interaction domain
  • EMMPRIN or CyP truncated EMMPRIN or CyP polypeptides
  • Such host animals include but are not limited to rabbits, mice, hamsters and rats.
  • adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.
  • BCG Bacille Calmette-Guerin
  • Corynebacterium parvum bacille Calmette-Guerin
  • Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.
  • Monoclonal antibodies which are homogeneous populations of antibodies to a particular antigen, are obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (Nature 256:495-497, 1975; and U.S. Pat. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., Immunology Today 4:72, 1983; Cole et al., Proc. Natl. Acad. Sci.
  • Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.
  • the hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.
  • chimeric antibodies are a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region (humanized).
  • single-chain antibodies are adapted to produce single- chain antibodies against EMMPRTN or CyP gene products.
  • Single-chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.
  • Antibody fragments that recognize specific epitopes are generated by known techniques.
  • such fragments include but are not limited to: the F(ab') 2 fragments, that are produced by pepsin digestion of the antibody molecule; and the Fab fragments, that are generated by reducing the disulfide bridges of the F(ab') 2 fragments.
  • Fab expression libraries are constructed (Huse et al., Science, 246:1275-1281, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
  • Antibodies to EMMPRTN or CyP are, in turn, utilized to generate anti-idiotype antibodies that "mimic" the EMMPRTN or CyP, using techniques well known to those skilled in the art. (Greenspan & Bona, FASEB J. 7:437-444, 1993; and Nissinoff, J. Immunol. 147:2429- 2438, 1991).
  • antibodies that bind to the CyP and competitively inhibit the binding of EMMPRIN to the EMMPRIN or CyP are used to generate anti-idiotypes that "mimic" the EMMPRTN or CyP and, therefore, bind and neutralize EMMPRIN.
  • Such neutralizing anti- idiotypes or Fab fragments of such anti-idiotypes are used in therapeutic regimens to neutralize EMMPRTN.
  • antibodies are generated against EMMPRIN that act as antagonists of EMMPRTN activity, i.e., inhibit the activation or signaling by EMMPRTN (as shown in Example 2, infra). Such antibodies are used therapeutically to treat, e.g., HIV-1 infection, AIDS and AIDS-related disorders, RA or cancer. Likewise, antibodies that act as agonists of EMMPRIN are generated. Such antibodies bind to EMMPRTN and activate its signal transducing activity.
  • kits e.g., EMMPRIN or CyP protein or cells expressing the EMMPRIN or CyP proteins
  • EMMPRIN or CyP protein or cells expressing the EMMPRIN or CyP proteins are packaged in a variety of containers, e.g., vials, tubes, microtitre well plates, bottles, and the like.
  • Other reagents can be included in separate containers and provided with the kit; e.g., positive controls samples, negative control samples, EMMPRTN or CyP proteins, peptides, buffers, cell culture media, antibodies, etc.
  • the following assays are designed to identify compounds or compositions that, among other art-recognized possibilities: bind to EMMPRIN, CyP or the CyP:EMMPRIN complex; that interfere with the interaction between CyP and EMMPRIN; or that effect EMMPRIN-mediated signal transduction or EMMPRTN-mediated cellular comparmentalization of proteins (e.g., HTV-1 MA and CA proteins).
  • Those compounds identified as antagonist or agonists of the CyP/EMMPRIN interaction, or as modifiers of EMMPRIN-mediated signal transduction or other EMMPRIN-mediated activities have therapeutic utility for the treatment and prevention of, e.g., HTV-1 infection, AIDS and AIDS- related disorders, RA or cancer.
  • the principle of the assays to identify compounds which inhibit the CyP/EMMPRIN interaction involves preparing a reaction mixture containing the test compound, functional CyP and EMMPRIN protein (or a cellular preparation comprising, in part, EMMPRIN protein), and incubating the reaction mixture for a time sufficient to allow the components to interact and bind (i.e., to form a complex which can be removed and/or detected).
  • the reaction mixture is prepared in the presence and absence of the test compound.
  • the test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of CyP and EMMPRTN proteins. Control reaction mixtures are incubated without the test compound or with a control agent.
  • any CyP:EMMPRIN complexes is then detected.
  • the formation of a complex in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound antagonizes the CyP/ EMMPRTN interaction.
  • complex formation within reaction mixtures containing the test compound and normal CyP and EMMPRTN proteins may also be compared to complex formation within reaction mixtures containing the test compound and derivatizied or mutant CyP or EMMPRTN proteins.
  • Homogeneous and heterogeneous assay formats Screening assays for antagonist and agonists of the CyP/EMMPRIN interaction are conducted in either homogeneous or heterogeneous formats.
  • Homogeneous assays are either cell-based or non-cell-based, wherein the entire reaction is carried out in a liquid phase.
  • Heterogeneous assays are generally (but not always; e.g., immobilized cells displaying cell-surface EMMPRIN) non-cell-based, and involve anchoring either the ligand or the receptor onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction.
  • test compounds that interfere with the ligand/receptor interaction are identified by conducting the reaction in the presence of the test substance; i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the ligand and interactive cellular or extracellular receptor.
  • test compounds that disrupt preformed complexes e.g., compounds with higher binding constants that displace one of the components from the complex
  • test compounds that disrupt preformed complexes are tested by adding the test compound to the reaction mixture after ligand/receptor complexes have been formed.
  • the various formats are described briefly below.
  • Heterogeneous cell-based and non-cell-based assays either the ligand, or the interactive cellular or extracellular receptor is anchored onto a solid surface, while the non-anchored species is labeled, either directly or indirectly.
  • microtitre plates are utilized.
  • the anchored species is immobilized by non-covalent or covalent attachments.
  • Non-covalent attachment is accomplished by coating the solid surface with a solution of the ligand, receptor proteins or cells expressing the receptor, and optionally drying.
  • an immobilized antibody specific for the species to be anchored is used to anchor the species to the solid surface.
  • the surfaces may be prepared in advance.
  • the assay is conducted by exposing the binding partner of the immobilized species to the coated surface with or without the test compound. Unreacted components are removed (e.g., by washing) after the reaction is complete, and any complexes formed will remain immobilized on the solid surface.
  • Detection of anchored complexes are accomplished in a number of ways not limited to the following.
  • a labeled antibody specific for the initially non-immobilized species the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody.
  • test compounds which inhibit complex formation or which disrupt preformed complexes are detected.
  • the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted components, and complexes then heterogeneously detected by, e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and detecting such anchored complexes using another labeled antibody specific for the other binding partner.
  • Test compounds that inhibit complex formation or that disrupt preformed complexes are identified, depending upon the order of reactant addition in the initial homogeneous liquid phase.
  • the ligand or receptor proteins are first prepared for immobilization using routine recombinant DNA techniques.
  • the ligand gene coding region is fused to a glutathione-S-transferase (GST) gene using a fusion vector, such as pGEX-5X-l, in such a manner that its binding activity is maintained in the resulting fusion protein.
  • GST glutathione-S-transferase
  • the interactive receptor is purified and used to raise a monoclonal antibody that can be labeled with the radioactive isotope I25 I.
  • the GST-ligand fusion protein is anchored to glutathione-agarose beads.
  • the interactive receptor is then added in the presence or absence of the test compound in a manner that allows interaction and binding to occur.
  • Unbound material is washed away at the end of the reaction period, and the labeled monoclonal antibody is added to the system and allowed to bind to the complexed components.
  • the ligand receptor interaction is detected by measuring the amount of radioactivity that remains associated with the glutathione- agarose beads. A successful inhibition of the interaction by the test compound results in a decrease in measured radioactivity.
  • the GST-ligand fusion protein and the interactive receptor are mixed together in liquid in the absence of the solid glutathione-agarose beads.
  • the test compound is added either during or after the species are allowed to interact. This mixture is then added to the glutathione-agarose beads and unbound material is washed away. The extent of inhibition of the ligand receptor interaction is detected by adding the labeled antibody and measuring the radioactivity associated with the beads.
  • the present invention provides a cell-based and a non-cell based heterogeneous assay, wherein the recombinantly expressed EMMPRIN protein, polypeptide or fusion protein, or CyP:EMMPRTN complex, or cells expressing the EMMPRIN receptor are attached to a solid substrate (e.g., test tube, microtitre well or a column).
  • a solid substrate e.g., test tube, microtitre well or a column.
  • the test compounds are then assayed for their ability to either bind to the immobilized EMMPRTN protein, polypeptide or fusion protein, or to the CyP:EMMPRIN complex, or for their ability to antagonize or promote the binding of CyP protein, polypeptide or fusion protein to the immobilized EMMPRIN protein, polypeptide or fusion protein.
  • the screens are designed to identify compounds that mimic the interaction between EMMPRTN and EMMPRIN ligands, such as CyPA or CyPB.
  • the test compounds are labeled, and are assayed for their ability to bind to immobilized EMMPRIN protein, polypeptide or fusion protein.
  • the screens are designed to identify compounds that antagonize the interaction between EMMPRIN and EMMPRTN ligands, such as CyPA or CyPB.
  • the EMMPRTN ligand is labeled and test compounds are assayed for their ability to antagonize the binding of labeled ligand to EMMPRIN.
  • Homogeneous cell-based and non-cell-based assays are either cell-based or non-cell-based, wherein the entire reaction is carried out in a liquid phase.
  • Cell-based assays A homogeneous, cell-based assay system is used to screen for compounds that modulate the activity of EMMPRTN to identify compounds for the treatment of, e.g., HIV-1 infection, AIDS, RA or cancer.
  • cells that endogenously express EMMPRTN or CyP are used to screen for compounds.
  • cell lines such as 293 cells, COS cells, CHO cells, MCF-7 cells, Hs578T cells, fibroblasts, and the like, are genetically engineered to express EMMPRTN or CyP are used for screening purposes.
  • host cells genetically engineered to express a functional EMMPRIN protein that responds to activation by CyP or CyP peptides or fusion proteins are used as an endpoint in the assay.
  • Such end points are provided by measurement of art-recognized changes in chemical, physiological, biological, or phenotypic properties, such as induction of a host cell gene or a reporter gene (e.g., MMPs), cAMP levels, adenylyl cyclase activity, calcium mobilization, host cell G-protein activity, host cell kinase activity, activation of signal transduction pathways, extracellular acidification rate, proliferation, differentiation, susceptibility to viral infection, receptor alterations (e.g., sensitization, desensitization, up- or down-regulation), etc.
  • the host cells expressing functional EMMPRTN or CyP proteins should provide for a significant EMMPRIN-based end-point response, preferably greater than 5-fold induction over background.
  • Host cells preferably possess a number of characteristics, depending on the readout, to maximize the EMMPRIN-based inductive response.
  • a set of assay conditions comprising: (a) a low natural level of cAMP, (b) a high level of adenylyl cyclase, (c) a high level of protein kinase A, (d) a low level of phosphodiesterases, and (e) a high level of cAMP response element binding protein is advantageous.
  • host cells are engineered to express a greater amount of favorable factors (e.g., enhanced or constitutive EMMPRTN and/or CyP expression when screening for compounds that act as EMMPRIN antagonists) or a lesser amount of unfavorable factors (e.g., enhanced CyP expression when screening for EMMPRTN agonists).
  • favorable factors e.g., enhanced or constitutive EMMPRTN and/or CyP expression when screening for compounds that act as EMMPRIN antagonists
  • unfavorable factors e.g., enhanced CyP expression when screening for EMMPRTN agonists
  • the cells expressing the EMMPRTN or CyP proteins are exposed to a test compound or controls. After exposure, the cells are assayed to measure the expression and/or activity of components of the EMMPRIN signal transduction pathway. Alternatively, the activity of the signal transduction pathway itself is assayed. For example, after exposure, cell lysates are assayed for calcium mobilization (see Example 3), induction of cAMP, or modulation of protein tyrosine kinase (PTK) (Example 3), serine/threonin kinases, g- proteins, Ras, PKA, RAP1, B-Raf, Mek, or MAPK activity or phosphorylation.
  • PTK protein tyrosine kinase
  • Activation or deactivation of particular signal transduction pathways and upstream activators can lead to activation or deactivation of many transcription factors, which in turn can mediate, among other things, cellular proliferation, differentiation, quiescence or death.
  • This is exemplified in the neuronal differentiation of PC12 cells by PKA's phosphorylation of active sites on a small GTP- binding protein, Rap 1, and subsequent activation of a serine/threonin kinase, B-Raf and the MAPK kinase, Mek which leads to activation of MAPK.
  • This same pathway has been implicated in the NE differentiation of specific prostate cancer cell lines, such as LNCaP and PC-3M.
  • EMMPRIN In screening for compounds that may act as agonists of EMMPRIN, it is advantageous to use cell lines that express little or no CyP to test for activation of signal transduction by the test compound as compared to controls. In screening for compounds that act as antagonists of EMMPRIN, it is advantageous to over-express CyP, or provide exogenous CyP, to test for inhibition of signal transduction by the test compound as compared to controls.
  • test compounds are selected based on their ability to regulate intracellular translocation of HIV-1 matrix (MA) and capsid (CA) proteins after viral infection.
  • Non-cell-based assays In addition to homogeneous cell-based assays, homogeneous non-cell-based assay systems are used to identify compounds that interact with, e.g., bind to EMMPRTN, CyP or to the CyP:EMMPRTN complex. Such compounds act as agonists or antagonists of EMMPRIN activity and are used in the treatment of, e.g., HTV-1 infection, AIDS, RA or cancer.
  • EMMPRIN proteins, polypeptides, fusion proteins or soluble EMMPRTN proteins are expressed and utilized (with or without CyP proteins, polypeptides or fusion proteins) in non-cell based assays to identify compounds that bind to EMMPRTN, CyP or the CyP:EMMPRIN complex.
  • polypeptides corresponding to one or more EMMPRTN or CyP domains, or fusion proteins containing one or more of the EMMPRTN or CyP domains are used in non-cell based assay systems to identify compounds that bind to EMMPRTN, CyP or to the CyP:EMMPPJN complex.
  • Compounds identified are therapeutically useful to modulate EMMPRIN-mediated activities, such as signal transduction.
  • assays based on fluorescent reporter moieties are examples of homogeneous non-cell-based assays.
  • Such assay for example, comprise a fluorescent "reporter moiety" and a "quencher moiety,” each covalently bound to linker moieties (e.g., phosphoramidites, or other appropriate linkers available in the art) whereby each is attached to one member of the interacting protein pair at issue (e.g., a reporter moiety attached to the ligand, and a quencher moiety attached to the interacting receptor).
  • linker moieties e.g., phosphoramidites, or other appropriate linkers available in the art
  • reporter and quencher molecules examples include 5' fluorescent reporter dyes 6FAM ("FAM"; 2,7 dimethoxy-4,5- dichloro-6-carboxy-fluorescein), TET (6-carboxy-4,7,2',7'-tetrachlorofluorescein), and the 3' quencher dye TAMRA (6-carboxytetramethylrhodamine) (Livak et al., PCR Methods Appl 4:357-362, 1995; Gibson et al., Genome Res. 6:995-1001; and 1996; Heid et al., Genome Res. 6:986-994, 1996).
  • 6FAM fluorescent reporter dye
  • TET 6-carboxy-4,7,2',7'-tetrachlorofluorescein
  • TAMRA 6-carboxytetramethylrhodamine
  • the reporter moiety emission is transferred efficiently to the quenching moiety, and the fluorescent-emission spectrum (e.g., at 518 run) is quenched or masked. However, on separation, the reporter moiety emission is no longer transferred efficiently to the quenching moiety, resulting in an increase of the reporter moiety fluorescent-emission spectrum.
  • fluorochromes are chosen such that the fluorescent intensity of the quenching moiety (e.g., TAMRA), changes very little over the course of the reaction.
  • TAMRA fluorescent intensity of the quenching moiety
  • Several factor influence the efficiency of such fluorescent-based assays including magnesium and salt concentrations, reaction conditions (time and temperature), protein sequence, size and composition. Optimization of these factors to produce the optimum fluorescence intensity for a given genomic locus is obvious to one skilled in the relevant art.
  • a preformed CyP:EMMPRIN complex is prepared in which either CyP or EMMPRIN (or both) is labeled with a suitable fluorescent tag, whereby the signal generated by the label or tag is quenched due to complex formation (see, e.g., U.S. Patent 4,109,496).
  • a test substance that competes with and displaces one of the species from the preformed complex results in the generation of a signal above background. In this way, test substances that antagonize the CyP:EMMPRIN interaction are identified.
  • compounds that affect EMMPRIN or CyP: EMMPRIN complex activity include but are not limited to compounds that bind to EMMPRTN, inhibiting or not inhibiting binding of the natural ligand (CyP), and that either activate signal transduction (agonists) or block activation (antagonists), and compounds that bind to CyP (e.g., soluble EMMPRIN proteins or peptides, or CsA derivatives) and thereby antagonize or enhance CyP-mediated EMMPRIN activity.
  • CyP e.g., soluble EMMPRIN proteins or peptides, or CsA derivatives
  • EMMPRIN signal transduction e.g., compounds that affect downstream signaling events, calcium mobilization (see Example 3), induction of cAMP, modulation of protein tyrosine kinase (PTK) (Example 3) or serine/threonin kinases, G proteins, Ras, PKA, RAP1, B-Raf, Mek, or MAPK activity or phosphorylation, which may participate in transducing the signal activated by CyP binding to the EMMPRTN) are also identified by the inventive assay procedures.
  • the present invention provides for the identification and use of such compounds that affect signaling events downstream of EMMPRTN and thus modulate effects of CyP and EMMPRTN on HTV infection, AIDS, RA and cancer.
  • EMMPRIN gene activity by affecting EMMPRTN gene expression, including molecules, e.g., proteins or small organic molecules, that affect transcription or interfere with splicing events so that expression of the full- length or the truncated form of EMMPRIN can be modulated
  • inventive assay procedures include molecules, e.g., proteins or small organic molecules, that affect transcription or interfere with splicing events so that expression of the full- length or the truncated form of EMMPRIN can be modulated.
  • Compounds which are screened in accordance with the invention include, but are not limited to peptides, antibodies and fragments thereof, and other organic compounds (e.g., peptidomimetics) that bind to EMMPRTN or the CyP:EMMPRTN complex and either mimic the activity triggered by CyP (i.e., agonists) or inhibit the activity triggered by CyP (i.e., antagonists); as well as peptides, antibodies or fragments thereof, and other organic compounds, including mutant or truncated EMMPRTN molecules (or a portion thereof) that bind to CyP and thereby "activate" or "neutralize” CyP-mediated EMMPRTN activity.
  • organic compounds e.g., peptidomimetics
  • Compounds include, but are not limited to peptides, such as soluble peptides, including but not limited to members of random peptide libraries; (Lam et al, Nature 354:82-84, 1991; Houghten et al., Nature 354:84- 86, 1991), and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries; e.g., Songyang et al., Cell 72: 67-778, 1993), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti- idiotypic, chimeric or single chain antibodies, and FAb, F(ab') 2 and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.
  • peptides such as soluble peptides, including but not limited to members of random
  • Other compounds which are screened in accordance with the invention include, but are not limited to, small organic molecules that are able to cross the blood-brain barrier, gain entry into an appropriate cell and affect the expression of the EMMPRIN gene or some other gene involved in the EMMPRIN signal transduction pathway (e.g., by interacting with the regulatory region or transcription factors involved in gene expression); or such compounds that affect the activity of EMMPRIN or the activity of some other intracellular factor involved in the EMMPRIN signal transduction pathway, such as, e.g., calcium mobilization, induction of cAMP, modulation of protein tyrosine kinase (PTK), serine/threonin kinases, G proteins, Ras, PKA, RAP1, B-Raf, Mek, or MAPK activity or phosphorylation.
  • PTK protein tyrosine kinase
  • Identification of the CyP EMMPRIN interaction also enables the application of art- recognized computer modeling (e.g., active site modeling based on X-ray crystallography, NMR, etc.) and database searching technologies to permit identification of compounds, or the improvement of already identified compounds, that can modulate EMMPRIN expression or activity.
  • art- recognized computer modeling e.g., active site modeling based on X-ray crystallography, NMR, etc.
  • database searching technologies e.g., database searching technologies to permit identification of compounds, or the improvement of already identified compounds, that can modulate EMMPRIN expression or activity.
  • EMMPRTN-mediated signal transduction can be used to treat, e.g., HIV-1 infection, AIDS and AIDS-related disorders, RA or cancer.
  • EMMPRTN-mediated signal transduction can be used to treat, e.g., HIV-1 infection, AIDS and AIDS-related disorders, RA or cancer.
  • the particular method, formulation and mode of administration will depend upon the therapeutic indication, and the physico-chemical properties of the compound, and the target organ or tissue. Different approaches are discussed.
  • antagonism of CyP-mediated EMMPRIN activity in vivo e.g., by administration of anti-EMMPRIN antibodies, or otherwise targeting downstream signaling events
  • antagonism of CyP-mediated EMMPRIN activity in vivo e.g., by administration of anti-EMMPRIN antibodies, or otherwise targeting downstream signaling events
  • agonists of CyP-mediated EMMPRIN activity are useful, for example to enhance normal tissue remodeling processes.
  • the therapeutic compound demonstrate absolute specificity for the CyP/EMMPRTN interaction.
  • compounds that agonize both EMMPRTN, and other unknown CyP interaction molecules could be used.
  • Such compounds could be administered so that delivery to joints, blood, breast tissue, the prostate, or elsewhere, is optimized to achieve, e.g., HIV-1 infection, AIDS, RA or cancer treatment, and so that potential side effects are minimized.
  • Compounds that do not demonstrate a specificity for the CyP/EMMPRIN interaction can be administered in conjunction with another therapy or drug to control the side- effects that may result from modulating other molecules (e.g., other CyP interacting proteins); however, compounds which demonstrate a preference or selectivity for the CyP/EMMPRIN interaction are preferred.
  • Toxicity and therapeutic efficacy of such compounds are determined by standard pharmaceutical and toxicologic procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
  • Compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose is typically estimated initially from cell culture assays.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture.
  • IC 50 i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms
  • levels in plasma are measured, for example, by high performance liquid chromatography.
  • a therapeutically effective dose further refers to that amount of the compound sufficient to inhibit HIV infection.
  • Therapeutically effective doses may be administered alone or as adjunctive therapy in combination with other treatments for HIV infection or associated diseases.
  • a therapeutically effective dose further refers to that amount of the compound sufficient to inhibit HIV infection, or to inhibit progression of AIDS-, RA- or cancer-related processes.
  • Therapeutically effective doses are administered alone or as adjunctive therapy in combination with other treatments for HIV infection or associated diseases.
  • Formulations and Use Techniques for the formulation and administration of the compounds of the instant application are found, for example, in "Remington's Pharmaceutical Sciences” Mack Publishing Co., Easton, PA, latest addition.
  • Pharmaceutical compositions for use in accordance with the present invention are formulated in a conventional manner using one or more physiologically acceptable carriers or excipients.
  • the compounds and their physiologically acceptable salts and solvates are formulated for administration through suitable routes including, e.g., inhalation or insufflation (either through the mouth or the nose), oral, buccal, rectal, transmucosal, or intestinal administration, parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, and optionally in a depot or sustained release formulation.
  • suitable routes including, e.g., inhalation or insufflation (either through the mouth or the nose), oral, buccal, rectal, transmucosal, or intestinal administration, parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, and optionally in a depot or sustained release formulation.
  • a targeted drug delivery system for example in a liposome coated with an anti-CD4 antibody.
  • liposomes are targeted to and taken up selectively by cells expressing CD4.
  • the pharmaceutical compositions take the form of, for example, tablets pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, prepared by conventional means with pharmaceutically acceptable excipients such as: binding agents (e.g., pregelatinised maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP)); fillers (e.g., lactose, sucrose, mannitol, or sorbitol, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch, sodium starch glycolate, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium al
  • Liquid preparations for oral administration are, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations are prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers, such as Han
  • the compounds may be formulated for parenteral administration by injection by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form in ampoules or in multi-dose containers, with an added preservative.
  • Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • the compounds may also be formulated as a depot preparation. Such long- acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion-exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc., or bases. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms.
  • Examples of pharmaceutically acceptable salts, carriers or excipients are well known to those skilled in the art and can be found, for example, in Remington's Pharmaceutical Sciences, 18th Edition, A.R. Gennaro, Ed., Mack Publishing Co., Easton, PA, 1990.
  • Such salts include, but are not limited to, sodium, potassium, lithium, calcium, magnesium, iron, zinc, hydrochloride, hydrobromide, hydroiodide, acetate, citrate, tartrate, malate sales, and the like.
  • compositions may, if desired, be presented in a pack or dispenser device that may contain one or more unit dosage forms containing the active ingredient.
  • the pack may, for example, comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • Additional methods which may be utilized to modulate the overall level of EMMPRIN gene expression and/or EMMPRTN activity in a patient include the introduction of appropriate recombinant (genetically engineered) or non-recombinant cells that express soluble EMMPRIN or CyP domains, fusion proteins thereof (e.g., fusion Ig molecules of EMMPRIN or CyP), or cyclophilin (including CyP) mutants, molecular decoys or other mimics of EMMPRTN or CyP that inhibit HIV infection or EMMMPRTN-mediated signal transduction, for instance by interfering with CyP/EMMPRIN interactions.
  • appropriate recombinant genetically engineered
  • non-recombinant cells that express soluble EMMPRIN or CyP domains, fusion proteins thereof (e.g., fusion Ig molecules of EMMPRIN or CyP), or cyclophilin (including CyP) mutants, molecular decoys or other mimics of EMMPRTN or CyP that inhibit HIV infection
  • Such cells are administered in vivo at the appropriate anatomical site (e.g., in the RA joint), or as part of a tissue graft located at a different site in the body where they may function as "bioreactors" that deliver a supply of the soluble molecules.
  • Such soluble EMMPRIN or CyP polypeptides and fusion proteins when expressed at appropriate concentrations, have utility in antagonizing or agonizing endogenous EMMPRTN activity, or in neutralizing, "moping up,” or “activating,” as the case may be, the native ligand for EMMPRIN (i.e., CyP) and thus act as modulators of EMMPRTN activity for the treatment, e.g., of HIV-1 infection, AIDS and AIDS-related disorders, RA and cancer.
  • Such cell-based gene therapy techniques are well known to those skilled in the art (Anderson et al., U.S. Pat. No. 5,399,349; Mulligan & Wilson, U.S. Pat. No. 5,460,959).
  • Example 1 EMMPRIN is a CyPA Interacting Protein
  • This example provides in vitro experiments using a Yeast Two-Hybrid protocol (Clontech Laboratories, Inc.; Palo Alto, CA) with CyPA as the "bait” (i.e., as the interaction target) to identify CyPA -interacting proteins by screening a cDNA "prey" library prepared from B lymphocytes.
  • CyPA a transmembrane protein
  • Yeast two-hybrid screening Briefly, a 'expressed sequence tag' identified as human CyPA was obtained from ATCC (ATCC #78809D). In vitro translation and sequencing confirmed that this sequence represented a full-length CyPA cDNA (essentially homologous to GenBank #Y00052). The sequence was cloned into the vector pAS2-l (ClonTech) to generate plasmid pAS2-l-CyPA encoding CyPA-GAL4 DNA-Binding Domain (BD) fusion protein. This plasmid was used as "bait" to screen a human B-cell cDNA library (i.e., the "prey” library) (from Dr. S. Fields, SUNY, Stony Brook) constructed in pSEl 107 encoding GAL4 Activation Domain (AD) (library complexity «10 s ).
  • AD GAL4 Activation Domain
  • the Isolated EMPRIN clone Approximately 10 6 cDNA clones were screened. Ten (10) clones were selected as true positives after several rounds of screening (see under "Methods” above) and sequenced. One of the clones, that interacted relatively strongly in our screen, carried an insert that was 97% identical in its sequenced 5' 186 nucleotides to human extracellular matrix metalloproteinase inducer (EMMPRTN) cDNA (DeCastro et al., J. Invest. Dermatol 106:1260-1265, 1996).
  • EMMPRTN extracellular matrix metalloproteinase inducer
  • EMMPRTN was selected for further analysis because it was the only transmembrane protein among the CyPA-interacting clones, which made it a good candidate for the role of a CyPA receptor ( Figure 1).
  • the DNA and protein sequences of EMMPRIN (human) are shown in [SEQ ID NO:l] and [SEQ ID NO:2], respectively.
  • EMMPRTN is a 269-amino acid highly glycosylated cell-surface protein, having a molecular weight of 50-60 kDa, and characteristic signal peptide (sp), extracellular (ecd), transmembrane (tm) and intracellular (icd) domains (Figure 1, left panel).
  • EMMPRIN belongs to the immunoglobulin (Ig) superfamily (Miyauchi et al., J Biochem.
  • EMMPRIN has been alternatively referred to as CD 147, basigin and M6-antigen in human (Miyauchi et al., J. Biochem.(Tokyo) 107:316-323, 1990; Kasinrerk et al., J. Immunol. 149:847-854, 1992), neurothelin and HT7 in chicken (Albrecht et al., Brain Res.
  • EMMPRIN is expressed on the cell surface of some tumor cells whereby, in culture, it stimulates fibroblasts to produce very high levels of coUagenase activity (Biswas et al., Cancer Res. 55:434-439, 1995).
  • Secretion of coUagenase and other metalloproteinases leads to degradation of extracellular matrix components of the basement membrane, a crucial step in tumor cell invasion and metastasis, and contributes to cartilage destruction in rheumatoid arthritis (McCachren, Arthritis Rheum. 34:1085-1093, 1991; Firestein, Arthritis Rheum. 39:1781-1790, 1996).
  • EMMPRIN is also expressed on a wide range of normal cells.
  • EMMPRIN is known to be involved in neuronal-glial cell interactions in retinal development (Fadool & Linser, Dev. Dyn. 196:252-262, 1993), and in regulation of immune responses and cell-cell recognition (Berditchevski et al., J. Biol. Chem. 272:29174-29180, 1997). Mice lacking basigin exhibit infertility of both sexes and show defects in short-term memory and learning (Igakura et al., Biochem. Biophys. Res. Commun. 224:33-3649, 1996).
  • EMMPRIN is up- regulated upon T cell activation by PHA. This up-regulation leads to dimerization of EMMPRIN on the surface and makes it easily recognizable for antibodies (Edwards & Haliett, Immunol Today 18:320-324, 1997).
  • an affinity resin binding analysis was performed using immobilized CyPA and in vitro transcribed and translated [ 35 S]-labeled EMMPRIN to confirm the EMMPRIN-CyPA interaction that was observed in the Yeast Two- Hybrid experiments.
  • Figure 1 shows that [ 35 S]-labeled EMMPRTN was specifically retained by CyPA-derivatized sepharose beads ( Figure 1, right-hand panel).
  • EMM.Cl containing ecd, tm and icd domains
  • EMM.C2 lacking the tm and icd domains
  • CyPA affinity resin was prepared by coupling recombinant human CyPA to sepharose according to manufacturers instructions. In brief, one gram of freeze-dried CNBr-activated Sepharose 4B (Pharmacia; Piscataway, N ) was rehydrated in 1 mM HC1, and washed for 15 minutes with 1 mM HC1
  • Binding reactions were performed for 90 min at room temperature in binding buffer (20 mM HEPES, pH 6.8; 150 mM KOAc; 2 mM Mg(OAc) 2 ; 2 mM DTT; 0.1% Tween 20; 0.1 mM PMSF, 1 ⁇ g/ml aprotinin, l ⁇ g/ml pepstatin).
  • EMMPRIN was specifically retained by CyPA-coated sepharose beads.
  • Aliquots of [ 35 S]-labeled EMMPRTN were incubated with CyPA affinity resin or with control resin. Bound proteins were eluted with standard Laemmli buffer and revealed by electrophoresis and autoradiography ( Figure 1, right-hand panel).
  • [ 35 S]-labeled EMMPRTN was specifically retained by CyPA sepharose beads, but not control beads lacking CyPA. This specific in vitro binding interaction was observed only with the full-length
  • EMMPRIN construct EMM.C2 (containing ecd, tin and icd domains), and not with the EMM.Cl EMMPRIN construct lacking the tm and icd domains.
  • CyPA binds to cell-surface EMMPRIN on intact cells and induces intracellular signaling (see below). These results most likely reflect a requirement for the EMMPRIN transmembrane and/or intracellular domains for proper presentation of an ecd CyP-binding site to CyPA on the sepharose beads, or a mechanism whereby, CyPA directly interacts with the tm domain, with either ecd or tm domains or with both domains.
  • Example 2 EMMPRIN is a Signaling Receptor for CyPA
  • This example provides in vitro experiments and assays demonstrating that EMMPRIN- transfected CHO cells expressed high levels of EMMPRTN on the cell surface, That CyPA and CyPB induced Ca 2+ mobilization in such CHO-EMMPRIN cells, and that CyP-induced Ca 2+ mobilization in such CHO-EMMPRIN cells was blocked by the addition of anti-EMMPRIN antibodies, indicating that EMMPRTN is a signaling receptor for CyP.
  • CHO cell lines are EMMPRIN-negative, but were transfected to express high levels of EMMPRIN. All human, and most mouse cell lines tested already expressed EMMPRIN. Therefore, CHO cells, that have no detectable EMMPRTN, were chosen to analyze molecular mechanisms of CyP-EMMPRIN interactions.
  • a heterogeneous population of CHO cells that had already been transiently transfected with a human EMMPRIN expression vector was obtained from Dr. Brian Toole (Tufts University; Boston, MA).
  • FIG. 1 shows a FACS analysis of the CHO clone (CHO-EMM) expressing the highest levels of EMMPRIN on its surface.
  • the CHO-EMM clone was expanded and used for all further experiments.
  • Ca 2+ mobilization assays were performed essentially as described in Sherry et al., Proc. Natl. Acad. Sci. USA. 95:1758-1763, 1998. Briefly, 3xl0 6 Fura-2-AM-loaded CHO or CHO-EMM cells (5xl0 6 cells per ml) were stimulated with 10 ⁇ g of human CyPA per sample, and fluorescence emission at 340 and 380 run was measured on a Perkin-Elmer Luminescence Spectrometer LS50B.
  • CyPA induced a characteristic Ca 2+ mobilization in CHO-EMM, but not in control CHO cells ( Figure 3, left-hand panel).
  • the results presented in Figure 3 were obtained using 10 ⁇ g/ml CyPA, because additional experiments demonstrated saturation of the signaling response at this concentration.
  • EMMPRTN is a signal-transducing receptor for CyPA.
  • CyPB CyP-induced Co 2 * flux in CHO-EMMPRIN cells was blocked by the addition ofanti- EMMPRIN antibodies.
  • Ca 2 * mobilization Ca 2+ mobilization assays were performed as described herein above, except that anti-CD 147 mAb (M6FT) (Research Diagnostic, Inc) and isotype control antibodies (33814X, Pharmingen) were added at a concentration 500 ng/ml during the Fura-2-AM loading step.
  • M6FT Anti-CD 147 mAb
  • isotype control antibodies 33814X, Pharmingen
  • This example provides in vitro experiments and assays demonstrating that CyP-induced, EMMPRIN-mediated Ca 2+ mobilization occurs through known intracellular signal transduction pathways. CyPA-induced Ca 2+ mobilization was measured in cells pretreated with inhibitors of various kinases known to be involved in the transduction of intracellular signals. Specifically, the tyrosine kinase inhibitor, genistein, completely abrogated CyPA-induced Ca 2+ flux in CHO- EMM cells that stably expressed EMMPRIN ( Figure 4).
  • CHO-EMMPRIN cells were first pretreated for 45 minutes, during Fura-2 loading of the cells, with the following agents: Bis- indolylmaleimide I (10 nM), a PKC inhibitor; PD98059 (100 ⁇ M), a MAPK inhibitor; and genistein (67 ⁇ M), a tyrosine kinase inhibitor. The cells were then stimulated with 10 ⁇ g/ml CyPA, and subjected to Ca 2+ mobilization analysis as described herein above.
  • Bordetella pertussis toxin (PTX; at 100 ng/ml), which inactivates signaling pathways mediated by members of the Gi-Go and Gt-protein family, or the PTX B-oligomer (100 ng/ml), which was recently shown to induce cross-desensitization of chemokine receptors (Alfano et al., J. Exp. Med. 190:597-606, 1999), were added 12 hr prior to stimulation with 10 ⁇ g/ml CyPA and Ca 2+ mobilization analysis.
  • PTX Bordetella pertussis toxin
  • MMP matrix metalloproteinase
  • CyPA treatment activated expression and release ofproMMP-1, and enhanced expression and release ofproMMP-3 by WI-38 fibroblasts.
  • the question of whether CyPA induces the expression of MMP-1, MMP-3, and MMP-9 was examined, because these three MMPs have been reported to be elevated in the synovial fluid of rheumatoid arthritis patients, and are believed to contribute to disease-related pathology (Sorsa et al., Semin. Arthritis Rheum. 22:44-53, 1992; Keyszer et al., J. Rheumatol 26:251-258, 1999; So et al., Rheumatology (Oxford).
  • Figure 5 shows that WI-38 fibroblasts treated with CyPA, but not untreated fibroblasts, expressed and released MMP-1 into the culture fluid. Additionally, CyPA enhanced the expression and release of MMP-3, which was otherwise constitutively secreted by these cells. MMP-9 was not detected in the supernatant fluids of untreated or CyPA-treated cells.
  • inactive zymogens e.g., proMMP-1 and proMMP-3
  • proteolytic enzymes released by surrounding cells and tissue e.g., proMMP-1 and proMMP-3
  • the inflamed RA joint relative to a normal joint, contains a marked increase in the number of neutrophils thought to be the source of enzymes which ultimately cleave proMMP-1 and proMMP-3 to their active forms.
  • Activated MMPs then act to degrade cartilage leading to joint destruction (Edwards & Haliett, Immunol. Today 18:320-324, 1997).
  • EMMPRIN both receives (i.e., as a signal- transducing cellular receptor) a signal via an extracelluar CyP ligand, and imparts (i.e., as an anchored, cell-surface "ligand") a signal via cell-cell adhesion-type interactions with a counter receptor on another cell.
  • This example provides in vitro experiments and assays showing, in CHO cells, that EMMPRIN is involved in HIV infection. Specifically, according to the present embodiment, the presence of cell-surface EMMPRIN had a substantial enhancing effect on a pre-integration step of cellular infection by MuLV-pseudotyped retroviruses carrying the HIV-1 core ( Figure 6).
  • Methods CHO cell lines. CHO cells, that do not express EMMPRIN, were initially used in DNA transfection experiments to investigate the role of EMMPRIN in HTV-1 infection.
  • HTV-1 -susceptible human cells that were tested (primary T cells and macrophages, T lymphocytic and monocytic, HOS, 293T, and HeLa cell lines) already expressed relatively high levels of EMMPRIN.
  • Several CHO-EMM clones were selected (see Example 2) from EMMPRTN-transfected CHO cells that were provided by Dr. Brian Toole, Tufts University, Boston, MA, and that expressed high levels of EMMPRIN. No EMMPRIN was detected in control (pcDNA-transfected) CHO cells.
  • CHO cells grown to 80% confluency in 75cc flasks were transfected with 10 ⁇ g of CD4 or CXCR4 expression vectors (pBABE-T4 and pBABE-CXCR4, respectively) using Fugene (Boehringer Mannheim) and following the manufacturer-provided protocol.
  • the transfection efficiency was typically 15-20%, as revealed by flow cytometric analysis.
  • Antibodies Anti-CD 147 mAb (UM-8D6) was obtained from Ancell Immunology Research Products (Bayport, MN), and isotype-matched (IgGl ⁇ ) control mAb was from BD PharMingen (San Diego, CA). Anti-CD4 mAb was from Beckton Dickinson (Parsippany, NJ). Infection with luciferase-expressing pseudotyped HIV-1 variants. Single-cycle assays with Env-pseudotyped, luciferase-expressing HTV-1 recombinants were performed essentially as previously described (Connor et al., J. Exp. Med.
  • pseudotyped luciferase reporter viruses were produced by co- transfection of 293T cells with a plasmid expressing an envelope-deficient NL4-3 construct, along with a plasmid expressing viral envelopes derived from either the X4 strain HxB2, or the amphotropic murine leukemia virus (MuLV).
  • Cells infected with pseudotyped virus (5 ng of p24 per 10 6 cells) were lysed using reporter lysis buffer (Promega) after 4 days in culture, and luciferase activity was measured in relative light units using a Dynex MLX microplate luminometer.
  • EMMPRIN enhanced CHO cell infection by MuLV pseudotyped HIV.
  • a luciferase activity analysis of infection of CHO-EMM or control CHO cells with recombinant luciferase- expressing HIV-1 pseudotyped with an amphotropic envelope of murine leukemia virus (MuLV) was performed to determine whether EMMPRTN enhanced HIV infection.
  • CHO-EMM or control (pcDNA-transfected) CHO cells were infected, in the presence or absence of 50 ⁇ g/ml of anti-CD147 (i.e., anti-EMMPRIN) mAb or isotype-matched control mAb, with luciferase-expressing HIV-1 (Luc-HTV-1) pseudotyped with Env derived from MuLV.
  • Heparinase III (3x10 " "* IU/ l) was added to cells prior to infection for 1 hr at 37°C. Luciferase expression was measured on day 4 post-infection and is presented as percentage of expression relative to control (CHO-pcDNA cells) taken as 100%.
  • EMMPRIN enhanced CHO cell infection by HIV-1 pseudotyped HIV.
  • CHO-EMM or control CHO cells were transiently transfected with CD4- and CXCR4-expressing vectors, and then infected with a luciferase-expressing HTV-1 construct pseudotyped with the LAV envelope to determine whether EMMPRIN enhanced replication of viruses pseudotyped with HTV-1 envelope.
  • CHO or CHO-EMM cells triplicate cultures of CHO or CHO-EMM cells were transiently transfected with CD4- expressing pBABE-T4 and CXCR4-expressing pBABE-CXCR4 and infected with Luc-HIV-1 pseudotyped with Env derived from HTV-1 AV , which depends on CD4 and CXCR4 for entry. Luciferase expression was detected as described herein above, and is presented as percentage of expression relative to control cells (CHO/CD4/CXCR4) taken as 100%.
  • EMMPRIN enhanced HIV infection at a stage preceding viral integration .
  • the amount of HTV-1 reverse transcription was measured in the presence or absence of anti-CD 147 mAb in infected CHO cells to determine if the enhancing effect of EMMPRIN on HTV infection was manifested at a stage preceding integration of the proviral DNA.
  • Duplicate cultures of CHO and CHO-EMM cells were transiently transfected with CD4- and CXCR4-expressing vectors, and then infected with luc-HIV-1 pseudotyped with either Env u v Qr g nv LA v m - ⁇ p resence of anti-CD147 mAb (UM-8D6) or isotype-matched control antibody.
  • Viral DNA was analyzed by PCR two hours after infection using LTR R U5 primers [SEQ ID NO:2] [SEQ ID NO:3], and probe [SEQ ID NO:4] specific for early reverse transcription products (Schmidtmayerova et al., J. Virol. 72:4633-4642, 1998). Results were quantified on a Direct Imager (Packard) and are presented as radioactivity associated with LTR/g ⁇ g-specific signal relative to control cells (isotype-treated CHO/CD4/CXCR4) taken as 100%.
  • EMMPRIN had an enhancing effect on a pre-integration step of cellular infection by retroviruses carrying the HIV-1 core. Significantly, this effect did not depend on the identity of Env used for pseudotyping. Thus, the activity of EMMPRIN in enhancing HIV-1 infection does not appear to depend on the nature of receptors used for entry.
  • the instant data are consistent with a mechanism whereby heparans, while potentially involved in gpl20-mediated attachment (Mondor et al., J. Virol. 72:3623-3634, 1998), do not contribute to the EMMPRrN-mediated enhancing effect on a HTV-1 infection step preceding viral integration.
  • Example 6 Cell-surface EMMPRIN had a Substantial Enhancing Effect on a Post-fusion, Pre- integration Step of HIV-1 Infection of Primary Human PBMC
  • This example provides in vitro experiments and assays showing that EMMPRIN is involved in HIV infection of human primary peripheral blood mononuclear cells (PBMC). Specifically, the presence of cell-surface EMMPRIN on PBMC had a substantial enhancing effect on a post-fusion, pre-integration step of cellular infection by T cell-adapted or macrophage-tophic HTV-1 strains, or by pseudotyped retroviruses carrying the HTV-1 core ( Figure 7A-E).
  • PBMC peripheral blood mononuclear cells
  • PBMC peripheral blood mononuclear cells
  • Human primary peripheral blood mononuclear cells PBMC
  • PBMC peripheral blood mononuclear cells
  • Cells were activated with PHA (5 ⁇ g/ml) for 2 days and were then infected with HIV-1 LAV or HIV-1 ADA (5xl0 3 cpm of RT activity per lxlO 6 cells) in the presence of various concentrations of anti-CD 147 mAb (UM- 8D6) or isotype-matched control mAb.
  • Virus replication was assayed by measuring RT activity in culture supernatants. Infection with luciferase-expressing pseudotyped HIV-1 variants.
  • Preparation of, and infection with pseudotyped Luc-HIV-1 strains was performed as described above under Example 5, except that the envelopes were derived from either LAV or ADA strains.
  • Virus attachment assay PHA-activated PBMC were incubated for 2 hours at 37°C with anti-CD147 mAb (UM-8D6; at 50 ⁇ g/ml), anti-CD4 mAb (5 ⁇ g/ml), or heparinase III ⁇ xlO " IU/ml), and then washed and incubated for one hour at 4°C with HTV-1 AV (10 ng/ml of p24). Antibodies, but not heparinase, were present during the one-hour incubation periods at 4°C with HTV-1 LAV . The amount of cell-bound viral p24 was assayed by ELISA after extensive washing of the cells.
  • Virus-cell fusion For analysis of virus-cell fusion, PHA-activated PBMC were incubated with HIV-1 LAV for 2 hr at 37°C in the presence or absence (i.e., "control") of the indicated antibody. Cells were treated with trypsin (0.025%) for 30 min at 37°C), lysed, and the internalized viral p24 was measured in the lysates by ELISA. The background of this assay (i.e., the 4°C "control”) was determined by incubating cells at 4°C with the virus but without antibody, and then transferring them to 37°C in the presence of trypsin. This value reflects the amount of virus that manages to enter cells in the presence of trypsin.
  • cells were lysed in standard PCR buffer with proteinase K.
  • the proteinase K was heat inactivated, and 25 ⁇ l aliquots were subjected to 35 cycles of PCR in a total volume of 50 ⁇ l containing 0.2 ⁇ M oligonucleotide primers, 200 ⁇ M of each deoxynucleotide, 50 mM KCl, 10 mM Tris (pH 8.3), 2 mM MgCl 2 , and 1.25 U of Taq DNA polymerase (Perkin-Elmer).
  • Each cycle comprised a 30-sec. denaturation step at 94°C, a 30-sec. annealing step (Tm-5°C for each pair of primers), and a 1-min.
  • LTR R/U5 sense primer (5'-GGCTAACTAGGGAACCCACTG-3') [SEQ ID NO:6]
  • antisense primer (5'- CTGCTAGAGATTTTCCACACTGAC-3') [SEQ ID NO:7]
  • probe 5'- TGTGTGCCCGTCTGTTGTGTG-3') [SEQ ID NO:8]
  • LTR/gag primers sense primer (5'- CAGATATCCACTGACCTTTGG-3 ') [SEQ ID NO:9]
  • antisense primer (5 '- GCTTAATACTGACGCTCTCGCA-3') [SEQ ID NO:10]
  • probe (5'- GAGGCTTAAGCAGTGGGTTC-3') [SEQ ID NO: 11] (see Schmidtmayerova et al., supra).
  • Subcellular fractionation and Western blot analysis Subcellular fractions of MT-4 cells infected with H_V-1 LA , were prepared using a previously published protocol (Bukrinskaya et al., J. Exp. Med. 188:2113-2125, 1998) with some modifications. Briefly, cells were pelleted and incubated on ice in a hypotonic buffer (10 mM HEPES, pH 6.9, 10 mM KCl, 0.1 mM PMSF and 1 ⁇ g/ml aprotinin) for 15 min. Cells were then disrupted by Dounce homogenization, and nuclei were pelleted at 1,500 x g for 5 min. and discarded.
  • hypotonic buffer 10 mM HEPES, pH 6.9, 10 mM KCl, 0.1 mM PMSF and 1 ⁇ g/ml aprotinin
  • the supernatant fraction was removed and centrifuged at 18,000 x g for 45 min. Supernatant from this second centrifugation was reserved, and is referred to herein as the "cytosolic" fraction.
  • NTENT buffer 150 mM NaCl, 10 mM Tris-HCl, pH 7.2, 1 mM EDTA, 1% Triton X-100, 0.1 mM PMSF and 1 ⁇ g/
  • Virus replication was assessed by RT activity in culture supernatants on day 21 ( Figure 7 A, left panel), or by luciferase activity on day 4 after infection (right panel). Results are presented as percentages of RT (using LTR R/U5 primers [SEQ ID NO:6] and [SEQ ID NO:7], and probe [SEQ ID NO:8]) or luciferase activity relative to controls (cells treated with isotype-matched irrelevant mAb; taken as 100%).
  • Anti-CD147 mAb U-8D6
  • isotype-matched control mAb inhibited replication of macrophage-tropic (ADA) and T cell line-adapted (LAV) HTV-1 strains in primary PBMC ( Figure 7 A, left panel).
  • ADA macrophage-tropic
  • LAV T cell line-adapted
  • Anti-CD147 mAb (UM-8D6) did not block HIV attachment to human PBMC.
  • the effect of anti-CD147 mAb (UM-8D6) on different early steps of HTV-1 replication (e.g., viral attachment, fusion, uncoating, etc.) in PBMC was analyzed to define the mechanism of its inhibitory activity on HTV infection (Figure 7B).
  • the viral attachment step was analyzed by incubating virus particles with the cells at 4°C, and then measuring the amount of cell-bound viral p24.
  • triplicate PBMC cultures were pre-treated at 37°C with anti-CD147 mAb (UM-8D6; at 50 ⁇ g/ml), anti-CD4 (5 ⁇ g/ml) mAb, or heparinase III (3X10 "4 IU/ml), and then washed and incubated with HTV-1 LAV (10 ng/ml of p24) at 4°C for 1 hr as described in this Example under "methods," above.
  • the amount of cell-bound p24 was assayed by ELISA, and the results are shown for one representative experiment out of three performed with cells from different donors.
  • anti-CD147 mAb U-8D6
  • HIV-1 LAV attachment was also reduced by pre-treatment of the cells with heparinase III, in accordance with the " postulated role of heparans in HIV-1 attachment (Saphire et al., EMBO J. 18:6771-6785, 1999 (Host CyPA mediates HTV-1 attachment to target cells via heparans); Mondor et al., J. Virol. 72:3623-3634, 1998 (HIV-1 attachment to HeLa CD4 + cells is CD4-independent, gpl20 dependent and requires cell-surface heparans).
  • anti-CD 147 mAb blocked HIV infection at a step somewhere between viral attachment and integration.
  • Anti-CD147 mAb neither blocked HIV Env-mediated fusion between PBMC and HeLa cells expressing HIV-1 ADA and LA V envelopes, nor reduced cellular intemalization of viral p24.
  • the effect of anti-CD 147 mAb (UM-8D6) on HTV-1 Env-mediated fusion between PBMC and HeLa cells expressing HIV-1 ADA and LAV envelopes was analyzed to determine if EMMPRTN is involved at the viral-cell fusion step of replication
  • Virus-cell fusion For analysis of virus-cell fusion, PBMC were incubated with HIV-1 AV as described herein under "Methods" in this Example, supra.
  • the anti-CD 147 mAb (UM-8D6) did not inhibit viral p24 intemalization, whereas, as expected, the anti-CD4 mAb reduced the amount of internalized p24 to background levels ( Figure 7C, right panel).
  • anti-CD 147 antibody did not reduce the amount of viral proteins that became resistant to trypsin digestion as a result of virus-cell fusion.
  • Anti CD147 mAb (UM-8D6) reduced the amount of both early and late HIV-1 reverse transcription.
  • a semi-quantitative PCR method was used to analyze the amount of HTV-1 - specific reverse transcription, a post-fusion process that is representative of the progressive maturation of the pre-integration complex (PIC) ( Figure 7D).
  • PHA-activated human PBMC were treated with either anti-CD 147 mAb (UM-8D6; at 50 ⁇ g/ml), or anti-CD4 mAb (2 ⁇ g/ml), or with the corresponding isotype-matched control mAb (50 ⁇ g/ml) 2 hr before infection with HTV-1.
  • HTV-1 reverse transcription was then performed 2 hr after infection of PBMCs with HTV-1 LAV as described above under "Methods,” using primers LTR R/U5 [SEQ ID NO:6] and [SEQ ID:NO:7], and probe [SEQ TD NO:8] specific for the "strong-stop" early reverse transcription products (Schmidtmayerova et al., J. Virol. 72:4633-4642, 1998).
  • the PCR results were quantified on a Direct Imager (Packard) and are presented as percentage of counts in treated, relative to antibody-untreated control (taken as 100%). Dilutions of 8E5/LAI cells containing one HIV-1 genome per cell (Folks et al., J. Exp. Med. 164:280-290, 1986) were used as PCR standards ( Figure 7D, lower-left panel). The data are representative of three independent experiments, performed in duplicate.
  • the anti-CD 147 mAb (UM-8D6) reduced the amount of the "strong-stop" reverse transcription product by approximately 2-fold (Figure 7D, upper-left and right-hand panels). This short DNA fragment is produced early after virus entry and its amount reflects initiation of reverse transcription (Zack et al., Cell 61 :213-222, 1990). As expected, anti-CD4 mAb reduced the amount of LTR R/U5 -amplified fragment even more dramatically ( Figure 7D, upper-left and right-hand panels), consistent with the herein-described effect of this mAb on virus attachment and virus-cell fusion ( Figures 7B and 7C).
  • Anti CD147 mAb (UM-8D6) blocked normal translocation of HIV-1 matrix (MA) and capsid (CA) proteins early after de novo infection, indicating that EMMPRIN was involved in HIV-1 uncoating.
  • Virus "uncoating" occurs soon after HIV infection, and involves dissociation of viral capsid protein (CA) from the viral matrix protein (MA) and nucleoprotein complex (Bukrinsky et al., Proc. Natl Acad. Sci. U.S.A 90:6125-6129, 1993; Miller et al., J. Virol. 71:5382-5390, 1997).
  • MA relocates from membranes to the cytoskeleton, while CA is retained in the cytosol (Boukrinskaya et al., J. Exp. Med. 188:2113-2125, 1998).
  • This pattern of protein rearrangements correlates with association of the HTV-1 reverse transcription complex with the cytoskeleton and suggests involvement of the cytoskeleton in the early steps of PIC formation (Bukrinskaya et al., J. Exp. Med. 188:2113-2125, 1998).
  • HTV-1 matrix (MA) and capsid (CA) proteins early after de novo infection was investigated to determine whether EMMPRIN was involved in the HIV-1 "uncoating" step during infection ( Figure 7E).
  • MT-4 cells were inoculated at 4°C with HIV-1 LAI in the presence of anti-CD 147 mAb (UM-8D6; at 50 ⁇ g/ml) or isotype-matched control mAb.
  • An aliquot (lxlO 6 cells) was withdrawn after 30 minutes for protein analysis (i.e., the 0 hr p.i. time-point sample) ( Figure 7E, upper panel), while the inoculated cultures were transferred to 37°C and incubated for 1.5 hr ( Figure 7E, lower panels).
  • Example 7 Viral Resistance to the Inhibitory Effect of Anti-CD147 mAb Correlated with Resistance to CsA
  • This example provides in vitro experiments and assays showing that HIV resistance to the inhibitory effect of anti-CD 147 mAb correlated with resistance to CsA, indicating that the antibody interfered with a CyPA-dependent step in virus infection.
  • replication of A224E (a CsA-resistant, CA mutant HTV strain) in human PBMC was resistant to treatment with anti-CD 147 mAb (UM-8D6) (Figure 8).
  • Methods Co-culture protocol for de novo HIV infection.
  • 293 T cells were transfected with molecular clones of isogenic wild-type or A224E CA mutant viruses, and cultured for 3 days in the presence or absence of CsA (1 ⁇ M). The cells were washed on day 3 post- transfection and either cultured for an additional 4 days without CsA, or used for co-culture with PHA-activated CD8 + T cell-depleted PBMC (20 blood mononuclear cells per one 293T cell) in the presence or absence of anti-CD147 mAb (UM-8D6; at 100 ⁇ g/ml) but without addition of CsA (to avoid virus-unrelated immunosuppressive effects of the drug on T cells that affected replication of both viruses).
  • CsA 1 ⁇ M
  • virus replication was assayed by reverse transcriptase (RT) activity in culture supernatants using LTR U/5 primers [SEQ ID NO:6] and [SEQ ID NO:7], and probe [SEQ ID NO:8] as described herein above under “Methods,” Example 6.
  • RT reverse transcriptase
  • Replication ofA224E (a CsA-resistant, CA mutant HIV strain) in human PBMC was resistant to treatment with anti-CD147 mAb.
  • CsA interacts with CyPA, and has been shown to thereby interfere with Gag (CA antigen portion)-CyPA interactions in vitro, block cyclophilin incorporation into virions, and inhibit replication of HTV-1 in cell culture. See summary herein under "Background,” supra. These data are consistent with a model whereby the interaction of Gag with CyPA is necessary for the formation of infectious HTV-1 virions (Sherry et al., Proc. Natl. Acad. Sci. U.S.A. 95:1758-1763, 1998).
  • CsA-resistant HIV strains e.g., strains with CA mutations that confer CsA resistance, a CyPA-dependant trait
  • infection by CsA-resistant HIV strains may reasonably be expected to be either not dependent on CyPA, or differentially affected by CyPA receptor antagonists.
  • 293T cells were transfected with molecular clones of HIV-1 NL4 . 3 ("WT") ( Figure 8, left panel) or mutant A224E ( Figure 8, right panel) viruses in the absence (“C") or presence ("CsA") of cyclosporin A (1 ⁇ M) as described herein above in this Example under “Methods.”
  • Virus- producing transfected cells were washed and cultured in quadruplicate for an additional 4 days with (“293T + CD4 + T cells”) or without (“293T”) addition of CD8 + T cell-depleted PBMC and anti-CD 147 mAb (UM-8D6; at 100 ⁇ g/ml).
  • Virus replication was assayed by measuring RT activity in culture supernatants as described above under "Methods.”. Results are presented as mean ⁇ SE.
  • the amount of virus produced in this system reflects the efficiency of de novo infection of T cells rather than accumulation of the virus produced from transfected 293T cells.
  • Anti- CD 147 mAb U-8D6 did not inhibit replication of the CsA-resistant A224E virus, whereas replication of the wild-type virus was significantly diminished.
  • A224E virus collected from CsA-treated 293T cells replicated to levels similar to those of the virus collected from untreated cells, consistent with its CsA-resistant phenotype (Braaten et al., J Virol. 70:5170-5176, 1996), whereas wild-type virus collected in the presence of CsA was significantly attenuated.
  • Example 8 Peptides Derived from the Transmembrane Region of EMMPRIN Substantially Inhibited Infection of CHO-EMM Cells and Human PBMC by Pseudotyped Retroviruses Carrying the HIV-1 Core This example provides in vitro experiments and assays showing that peptides derived from the transmembrane region of the EMMPRTN protein inhibit HTV-1 infection.
  • an eight-amino acid polypeptide ([SEQ ID NO:3]) corresponding in sequence to a region at the amino-terminal end of the EMMPRTN transmembrane domain (see [SEQ ID NO:2]) blocked infection of CHO-EMM cells ( Figure 9) and human PBMC by Env ⁇ "- and Env ⁇ - pseudotyped luc-HIV-1 viruses, respectively.
  • CHO cell lines infection of CHO cells with E ⁇ -pseudotyped luc-HIV-1 variants and single-cycle luciferase assays were as described herein above under “Methods,” Example 5.
  • Preparation and infection of PHA-activated human PBMC with Env ADA - pseudotyped luc-HIV-1 was as described herein above under “Methods,” Example 5 and Example 6.
  • PBMC Lucifererase assays were performed as described for CHO cell lines.
  • Peptides Peptides 1 [SEQ ID NO:3], 2 [SEQ ID NO:4] and scrambled peptide 1 [SEQ ID NO:5] were obtained as custom polypeptides from Research Genetics (Huntsville, Alabama). Peptide derived from the transmembrane region of CD147 inhibits MuL V-pseudotyped
  • the EMMPRTN transmembrane domain corresponds to amino acids 204-228 of the EMMPRTN protein sequence [SEQ ID NO:2].
  • peptides corresponding to sub-regions within the EMMPRIN transmembrane region were prepared to determine whether they could inhibit HIV-1 infection.
  • Peptide 1 (LAALWPFL) is an eight-amino acid sequence [SEQ ID NO:3] corresponding to amino acids 206-213 of EMMPRTN.
  • Peptide 2 (GIVAEVLVL) is a nine-amino acid polypeptide sequence [SEQ ID NO:4] corresponding to amino acids 214-222 of EMMPRTN.
  • “Scrambled peptide 1" (FAWPLLLA), the randomized sequence control, was made according to a randomized sequence of the amino acid residues of peptide 1.
  • CHO and CHO-EMM (“CHO.CD 147") cells were infected as described above with recombinant luciferase-expressing HTV-1 pseudotyped with MuLV envelop in the presence of the indicated concentrations of peptides 1, 2, or scrambled peptide 1, or with no peptide. Luciferase expression was measured on day 4 post-infection using a luminometer.
  • FIG. 9 shows that MuLV-psueudotyped HTV-1 infection of CHO-EMM cells was substantially and specifically inhibited by peptide 1 [SEQ ID NO:3] in a concentration- dependent manner. HTV-1 infection was essentially blocked in the presence of 1 nM peptide 1. Neither peptide 2, nor scrambled peptide 1 inhibited HTV-1 infection in this assay.
  • Peptide derived from the transmembrane region ofCD147 inhibits HIV-1 infection of human PBMC.
  • PHA-activated human PBMC cultures were infected with EnV ⁇ -pseudotyped luc-HTV-1 in the presence of the indicated concentrations of peptides 1, 2 or scrambled peptide 1.
  • Env-pseudotyped luc-HTV-1 infection of PBMC was essentially blocked in the presence of 1 nM peptide 1.
  • Example 1 The above-identified activity of peptide 1 ([SEQ ID NO:3]) in inhibiting infection of CHO- EMM cells and PBMC by Env 1 ⁇ - and Env ⁇ -pseudotyped luc-HTV-1, respectively, is relevant to the interpretation of data presented herein above under "Example 1," regarding the retention of EMMPRTN by CyPA-coated sepharose beads.
  • Example 1 the specific in vitro binding interaction between EMMPRIN and CyPA was observed only with the full-length EMMPRIN (containing ecd, tm and icd domains) protein, and not with EMMPRTN lacking the tm and icd domains.
  • CyP/EMMPRIN interaction whereby CyP directly interacts with a region of the EMMPRTN transmembrane domain, and where said interaction was effectively antagonized by peptide 1 ([SEQ ID NO:3]) on both CHO-EMM cells and PBMC.
  • Agents that modify the CyP/EMMPRIN binding interaction have utility for the treatment or prevention of conditions characterized by local or systemic CyP release, synthesis or binding such as HIV-1 infection, AIDS and AIDS-related disorders, RA and Cancer.
  • RA Rheumatoid Arthritis
  • EMMPRIN Rheumatoid Arthritis
  • EMMPRTN had no known ligand prior to the present invention, and was believed only to be a potential adhesion molecule capable of mediating (i.e., acting as a cell-surface "ligand") cell-cell interactions.
  • examples and embodiments of the present invention demonstrate that CyP induces signal transduction in CHO-EMM cells that constitutively express EMMPRTN on their surface. This response was shown to be specific, because it was blocked by the addition of anti- EMMPRIN specific antibodies. Moreover, the tyrosine kinase inhibitor Genistein completely abrogated CyP-induced Ca 2+ mobilization in CHO-EMM cells, indicating that EMMPRIN- mediated Ca 2+ mobilization occurs through known intracellular signal transduction pathways.
  • CyPA is chemotactic for neutrophils (Sherry et al., Proc. Natl Acad. Sci. USA 89:3511-3515, 1992; Xu et al., J. Biol Chem. 267:11968-11971, 1992; Leiva & Lyttle, Btoc/jem. Biophys. Res. Commun. 186:1178-1183, 1992), and that CyPA is markedly up-regulated in the joints of patients with active RA disease and correlates with RA disease severity (Billich et al., J. Exp. Med.
  • the anti- CD 147 i.e., anti- EMMPRTN
  • U-8D6 the anti- EMMPRTN mAb
  • U-8D6 blocked a step in HIV-1 replication following virus-cell fusion but preceding formation of the functional pre-integration complex (PIC) that supports reverse transcription.
  • EMMPRIN facilitates virus uncoating and translocation into the subcellular compartment (i.e., cytoskeleton) where reverse transcription can take place.
  • anti-CD 147 U-8D6
  • U224E CsA-resistant HIV-1 mutant
  • A224E carrying a CA protein mutation
  • HIV virus commandeers the whole CyPA/EMMPRIN interaction pathway for its purposes.
  • the present invention also provides a method of treatment for cancer and many connective tissue diseases.
  • a utility is supported by (1) the fact that EMMPRTN-expressing tumor cells have been shown to up-regulate the expression of MMPs in fibroblasts co-cultured therewith (Biswas et al., Cancer Res. 55:434-439, 1995), (2) CyP activated and/or enhanced MMP production in human fibroblasts, as disclosed herein, and (3) the deregulated action of MMPs contributes to the pathological destruction of the extracellular matrix in many connective tissue diseases including, e.g., arthritis, periodontitis, tissue ulceration, and in cancer cell invasion and metastasis (Kahariet al., Exp.
  • GAG CTA CAC ATT GAG AAC CTG AAC ATG GAG GCC GAT CCC GGC CAG 591 Glu Leu His lie Glu Asn Leu Asn Met Glu Ala Asp Pro Gly Gin 170 175 180
  • TTGTCTGTGC ATCCGGGGGC AGCTCTGGAG GGGGTTTGCT GGGGAACTGG 1462
  • EMMPRIN extracellular matrix metalloproteinase inducer
  • MOLECULE TYPE DNA oligonucleotide
  • HYPOTHETICAL no
  • TITLE Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4- mediated pathway: replication is restricted at a postentry level
  • NAME/KEY HIV-1 LTR sequence
  • D OTHER INFORMATION: R/U5 antisense primer
  • x PUBLICATION INFORMATION:
  • T-lymphotropic strains enter macrophages via a CD4- and CXCR4- mediated pathway: replication is restricted at a postentry level
  • MOLECULE TYPE DNA oligonucleotide
  • HYPOTHETICAL no
  • ANTI -SENSE
  • TITLE Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4- mediated pathway: replication is restricted at a postentry level
  • MOLECULE TYPE DNA oligonucleotide
  • HYPOTHETICAL no
  • TITLE Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4- mediated pathway: replication is restricted at a postentry level
  • TITLE Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4- mediated pathway: replication is restricted at a postentry level
  • MOLECULE TYPE DNA oligonucleotide
  • HYPOTHETICAL no
  • TITLE Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4- mediated pathway: replication is restricted at a postentry level

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Des exemples et des modes de réalisation de l'invention montrent, entre autres, que la protéine inductrice de métalloprotéinase matricielle extracellulaire (EMMPRIN), déjà connue, appelée également CD147, constitue un récepteur cellulaire transducteur de signal pour la cyclophiline (CyP). L'invention concerne des méthodes de traitement de l'infection par VIH, du sida, de troubles liés au sida, de la polyarthrite rhumatoïde (RA), des troubles tissulaires associés, du cancer ou de tout état caractérisé par une sécrétion, synthèse ou fixation locale ou systémique de CyP, lesdites méthodes utilisant l'interaction CyP/EMMPRIN comme nouvelle cible d'intervention thérapeutique. L'invention concerne en outre des compositions pharmaceutiques comprenant des anticorps anti-EMMPRIN, et des protéines et peptides EMMPRIN solubles qui agissent par inhibition de l'interaction CyP/EMMPRIN. L'invention concerne également des méthodes de criblage pour identifier des composés qui inhibent l'interaction CyP/EMMPRIN.
PCT/US2001/025178 2000-08-10 2001-08-10 Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline WO2002013763A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002418303A CA2418303A1 (fr) 2000-08-10 2001-08-10 Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline
IL15435801A IL154358A0 (en) 2000-08-10 2001-08-10 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
EP01962087A EP1309346A4 (fr) 2000-08-10 2001-08-10 Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline
AU2001283295A AU2001283295A1 (en) 2000-08-10 2001-08-10 Treatment of HIV-1 infection and inflammatory disease using cyclophilin receptor antagonists
JP2002518911A JP2004505997A (ja) 2000-08-10 2001-08-10 シクロフィリン受容体アンタゴニストを用いるｈｉｖ−１感染および炎症性疾患の治療

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63703300A 2000-08-10 2000-08-10
US09/637,033 2000-08-10

Publications (2)

Publication Number Publication Date
WO2002013763A2 true WO2002013763A2 (fr) 2002-02-21
WO2002013763A3 WO2002013763A3 (fr) 2002-08-15

Family

ID=24554263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025178 WO2002013763A2 (fr) 2000-08-10 2001-08-10 Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline

Country Status (6)

Country Link
EP (1) EP1309346A4 (fr)
JP (1) JP2004505997A (fr)
AU (1) AU2001283295A1 (fr)
CA (1) CA2418303A1 (fr)
IL (1) IL154358A0 (fr)
WO (1) WO2002013763A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632243A1 (fr) * 2003-05-15 2006-03-08 Zhi Nan Chen Utilisation de la molecule hab18g/cd147 comme cible pour l'elaboration d'antagoniste antiviral, et antagoniste antiviral correspondant
EP1732599A1 (fr) * 2004-03-25 2006-12-20 Centocor, Inc. Utilisation d'antagonistes de l'inducteur de metalloproteinase dans la matrice extracellulaire pour le traitement de maladies associees a un angiogenese excessive
EP2303325A2 (fr) * 2008-05-23 2011-04-06 UTI Limited Partnership Inhibition d'emmprin pour traiter la sclérose en plaques
US8007808B2 (en) * 2008-04-04 2011-08-30 The Board Of Trustees Of The Univeristy Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
US8338171B2 (en) * 2009-08-31 2012-12-25 Centocor Ortho Biotech Inc. Baboon homolog of human CD147
US10365280B2 (en) * 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
CN111420048A (zh) * 2020-03-11 2020-07-17 中国人民解放军第四军医大学 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用
CN117187190A (zh) * 2023-11-07 2023-12-08 深圳湾实验室 抗亲环素a单抗及其在类风湿性关节炎治疗中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5080252B2 (ja) * 2004-07-23 2012-11-21 ジーイー・ヘルスケア・ユーケイ・リミテッド 細胞周期を知らせる細胞系
JP4911950B2 (ja) * 2005-11-07 2012-04-04 晃 伊東 Ｍｍｐ−１の部分ペプチドを用いた癌浸潤・転移阻害薬
JP2015524418A (ja) * 2012-07-27 2015-08-24 アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 血管内皮細胞への髄膜炎菌の線毛媒介接着の受容体としてのｃｄ１４７

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840305A (en) * 1996-03-14 1998-11-24 The Picower Institute For Medical Research Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
KR20010034554A (ko) * 1998-03-03 2001-04-25 레이몬드, 엠. 위티 치료제로서의 ｃｄ147 결합 분자

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FAIRLIE ET AL.: 'Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing' J. MED. CHEM. vol. 43, 2000, pages 1271 - 1281, XP002950831 *
GUO ET AL.: 'Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 272, no. 1, 03 January 1997, pages 24 - 27, XP002950832 *
KOIVUNEN ET AL.: 'Tumor targeting with a selective gelatinase inhibitor' NATURE BIOTECHNOLOGY vol. 17, August 1999, pages 768 - 774, XP000941541 *
KONTTINEN ET AL.: 'Increased expression of extracellular matrix metalloproteinase inducer in rheumatoid synovium' ARTHRITIS AND RHEUMATISM vol. 43, no. 2, February 2000, pages 275 - 280, XP002950830 *
YURCHENKO ET AL.: 'CD147 is a signaling receptor for cyclophilin B' BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 288, 2001, pages 786 - 788, XP002950829 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632243A1 (fr) * 2003-05-15 2006-03-08 Zhi Nan Chen Utilisation de la molecule hab18g/cd147 comme cible pour l'elaboration d'antagoniste antiviral, et antagoniste antiviral correspondant
EP1632243A4 (fr) * 2003-05-15 2007-12-26 Zhi Nan Chen Utilisation de la molecule hab18g/cd147 comme cible pour l'elaboration d'antagoniste antiviral, et antagoniste antiviral correspondant
EP1732599A1 (fr) * 2004-03-25 2006-12-20 Centocor, Inc. Utilisation d'antagonistes de l'inducteur de metalloproteinase dans la matrice extracellulaire pour le traitement de maladies associees a un angiogenese excessive
EP1732599A4 (fr) * 2004-03-25 2008-05-14 Centocor Inc Utilisation d'antagonistes de l'inducteur de metalloproteinase dans la matrice extracellulaire pour le traitement de maladies associees a un angiogenese excessive
US8182819B2 (en) 2008-04-04 2012-05-22 The Board Of Trustees Of The University Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
US8007808B2 (en) * 2008-04-04 2011-08-30 The Board Of Trustees Of The Univeristy Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
EP2303325A2 (fr) * 2008-05-23 2011-04-06 UTI Limited Partnership Inhibition d'emmprin pour traiter la sclérose en plaques
EP2303325A4 (fr) * 2008-05-23 2012-09-19 Uti Limited Partnership Inhibition d'emmprin pour traiter la sclérose en plaques
US8338171B2 (en) * 2009-08-31 2012-12-25 Centocor Ortho Biotech Inc. Baboon homolog of human CD147
US10365280B2 (en) * 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
US11391739B2 (en) 2014-10-02 2022-07-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
CN111420048A (zh) * 2020-03-11 2020-07-17 中国人民解放军第四军医大学 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用
CN111420048B (zh) * 2020-03-11 2023-09-19 中国人民解放军第四军医大学 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用
CN117187190A (zh) * 2023-11-07 2023-12-08 深圳湾实验室 抗亲环素a单抗及其在类风湿性关节炎治疗中的应用

Also Published As

Publication number Publication date
AU2001283295A1 (en) 2002-02-25
IL154358A0 (en) 2003-09-17
WO2002013763A3 (fr) 2002-08-15
EP1309346A2 (fr) 2003-05-14
EP1309346A4 (fr) 2005-06-01
JP2004505997A (ja) 2004-02-26
CA2418303A1 (fr) 2002-02-21

Similar Documents

Publication Publication Date Title
Tanaka et al. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.
Hooper et al. Membrane protein secretases
Dong et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation.
US7063971B2 (en) Phosphodiesterase enzymes
JP2000023682A (ja) ホスホジエステラ―ゼ酵素
CA2146328C (fr) C-c ckr-1, recepteur c-c chemokine
JP2001501444A (ja) Ｏｂ受容体ならびに体重障害の診断および治療の方法
US20030229203A1 (en) Chemokine variants and methods of use
KR100536394B1 (ko) Fas/ap01수용체들의기능조절인자
CA2259143C (fr) Sous-unite de regulation p101 de la phosphatidylinositol-3'-kinase regulee par une proteine g-beta-gamma
EP1309346A2 (fr) Traitement de l'infection par vih-1 et de maladies inflammatoires au moyen d'antagonistes du recepteur de la cyclophiline
US5721104A (en) Screening assay for anti-HIV drugs
AU719816B2 (en) Phospholipase C homolog
US20030185828A1 (en) Novel aggrecanase
CA2223038A1 (fr) Recepteur du genre c5a a sept transmembranes
WO1998020126A1 (fr) Sequences nucleotidiques codant des proteines associees de phosphatidylinositol-3 kinase et leurs utilisations
US7060810B2 (en) Regulation of human eosinophil serine protease 1-like enzyme
Miller et al. Phosphorylation and degradation of HMG CoA reductase
US20060211037A1 (en) Novel mouse CXC chemokine receptor
CA2217010A1 (fr) Nouvel homologue de cathepsine c
US6613506B1 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6187909B1 (en) Viral encoded semaphorin protein receptor polypeptides
WO2004061088A2 (fr) Compositions et methodes d'inhibition d'une infection par le virus de l'immunodeficience humaine par regulation vers l'aval de genes cellulaires humains
CA2121302A1 (fr) Recepteur viral amphotrope
WO2004053094A2 (fr) Compositions et procedes permettant d'inhiber l'infection par le virus de l'immunodeficience acquise par freination des genes cellulaires humains

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2418303

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 154358

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002518911

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001283295

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200301624

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001962087

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001962087

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001962087

Country of ref document: EP